Immunogenicity and Safety of Tetravalent Dengue Vaccine C... | NCT03746015 | Trialant
NCT03746015
Sponsor
Takeda
Status
Completed
Last Update Posted
Sep 8, 2025Actual
Enrollment
30Actual
Phase
Phase 2
Conditions
Dengue Fever
Interventions
TDV
Countries
United States
Protocol Section
Identification Module
NCT ID
Results Section
Participant Flow Module
Pre-assignment Details
Annotation Section
No data available
No data is available for this block.
Document Section
Large Document Module
Document Has No Statistical Analysis Plan (SAP)
Derived Section
Miscellaneous Info Module
Version Holder
NCT03746015
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
DEN-210
Secondary IDs
Not provided
Brief Title
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
Official Title
An Open-Label, Phase 2 Trial to Investigate the Humoral and Cell-Mediated Immune Responses and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Flavivirus-Naïve and Dengue-Immune Healthy Adults
Acronym
Not provided
Organization
TakedaINDUSTRY
Status Module
Record Verification Date
Aug 2025
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
No
Start Date
Dec 28, 2018Actual
Primary Completion Date
Mar 1, 2021Actual
Completion Date
Mar 1, 2021Actual
First Submitted Date
Nov 13, 2018
First Submission Date that Met QC Criteria
Nov 15, 2018
First Posted Date
Nov 19, 2018Actual
Results Waived
Not provided
Results First Submitted Date
Mar 12, 2024
Results First Submitted that Met QC Criteria
Mar 12, 2024
Results First Posted Date
Apr 10, 2024Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Feb 23, 2022
Certification/Extension First Submitted that Passed QC Review
Feb 23, 2022
Certification/Extension First Posted Date
Feb 25, 2022Actual
Last Update Submitted Date
Aug 19, 2025
Last Update Posted Date
Sep 8, 2025Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
TakedaINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
The purpose of this study is to assess the neutralizing antibody response against each dengue serotype post-vaccination.
Detailed Description
The vaccine being tested in this study is Takeda's Tetravalent Dengue Vaccine Candidate (TDV). TDV is being tested to protect people against dengue fever. This study will look at the immunogenicity and safety of TDV in flavivirus-naïve and dengue-immune adults.
The study will enroll approximately 44 patients. Participants will be categorized into two groups based on results from serological testing performed by the trial center outside the scope of this trial (up to 70 days [10 weeks] prior to Day 1 [Month 0]):
Group 1: Flavivirus-Naïve Participants Group 2: Dengue-Immune Participants
All participants will receive subcutaneous injection of TDV on Day 1 (Month 0) and Day 90 (Month 3).
This trial will be conducted in the United States. The overall time to participate in this study is 12 months. Participants will make multiple visits to the clinic, and 9 months after last dose of study drug for a follow-up assessment.
Conditions Module
Conditions
Dengue Fever
Keywords
Vaccine
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
30Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
TDV: Flavivirus-naïve
Experimental
Tetravalent Dengue Vaccine (TDV) 0.5 mL, subcutaneous (SC) injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
Biological: TDV
TDV: DENV Immune: DENV-1 Positive
Experimental
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by wild type dengue virus serotype-1 (DENV-1) were included in this group.
Biological: TDV
TDV: DENV Immune: DENV-3 Positive
Experimental
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-3 were included in this group.
Biological: TDV
Interventions
Name
Type
Description
Arm Group Labels
Other Names
TDV
Biological
TDV subcutaneous injection comprised of 1 molecularly characterized, attenuated dengue virus strain, and 3 chimeric dengue virus strains with potencies of not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) per dose of TDV-1, TDV-2, TDV-3, and TDV-4, respectively.
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by microneutralization test 50% (MNT50).
Day 15
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 30 (Month 1)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Day 30 (Month 1)
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 60 (Month 2)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Day 60 (Month 2)
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 90 (Month 3)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Day 90 (Month 3)
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 105
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Day 105
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 120 (Month 4)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Secondary Outcomes
Measure
Description
Time Frame
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
IFN-γ ELISpot response >3 times higher compared with baseline (no peptide) and ≥5 spots per 10^6 peripheral blood mononuclear cells (PBMCs) was defined as cellular immune response. Cellular immune response to any peptide pool was reported. The peptide pools included pre-membrane envelope (prME), capsid (C), non-structural proteins (NS): NS1, NS2, NS3, NS4 and NS5 for DENV-1, DENV-2, DENV-3 and DENV-4.
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.
Group 1 only: immunologically naïve to dengue, Zika, Yellow Fever (YF), Japanese Encephalitis (JE), West Nile (WN) (based on negative results for detection of anti-DENV, anti-Zika, anti-YF, anti-JE, anti-WN antibodies) as documented by serological testing performed by the trial center outside the scope of this trial (up to 70 days [10 weeks] prior to Day 1 [Month 0]).
Group 2 only: serology consistent with primary infection with either DENV-1 or DENV-3 (defined as detectable neutralizing antibodies against DENV-1 or DENV-3 only, or titers for DENV-1 or DENV-3 ≥4-times higher than titers for the 2 other dengue serotypes) as documented by serological testing performed by the trial center outside the scope of this trial (up to 70 days [10 weeks] prior to Day 1 [Month 0]).
Exclusion Criteria:
Has clinically active significant infection (as assessed by the investigator) or body temperature ≥38°C (100.4°F) within 3 days of the intended date of vaccination.
Known or suspected impairment/alteration of immune function including:
Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks and/or ≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0) (use of inhaled, intranasal, or topical corticosteroids is allowed).
Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks and/or ≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0).
Administration of immunoglobulins and/or any blood products within 3 months prior to Day 1 (Month 0) or planned administration during the trial.
Receipt of immunostimulants within 60 days prior to Day 1 (Month 0).
Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (Month 0).
Known Human Immunodeficiency Virus (HIV) infection or HIV-related disease.
Hepatitis C virus infection.
Genetic immunodeficiency.
Has planned vaccination (during the trial conduct) against any non-dengue flavivirus (eg, Zika, YF, JE, WN, tick-borne encephalitis, or Murray-Valley encephalitis).
Planned travel (during the trial conduct) to any area endemic for dengue.
Mandaric S, Friberg H, Gottardo R, Messer W, Tricou V, Faccin A, Roubinis N, Nadeem I, Gray L, Sharma M, Currier JR, Biswal S. Humoral and cellular responses to a tetravalent dengue vaccine (TAK-003) in adults from a dengue non-endemic region: An open-label phase 2 trial. Vaccine. 2026 Apr 2;77:128373. doi: 10.1016/j.vaccine.2026.128373. Epub 2026 Feb 20.
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Types
Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame
Not provided
Access Criteria
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Healthy participants were enrolled in this study to receive Tetravalent Dengue Vaccine (TDV) on Days 1 and 90. One participant did not meet the randomization criteria and was not allocated to any of the pre-defined study groups and was excluded from all analyses except safety analysis.
Recruitment Details
Participants took part in the study at 2 investigative sites in the United States from 28 December 2018 to 1 March 2021.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
FG000
TDV: Flavivirus-naïve
Tetravalent Dengue Vaccine (TDV) 0.5 mL, subcutaneous (SC) injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants who were flavivirus-naïve were included in this group.
FG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by wild type dengue virus serotype-1 (DENV-1) were included in this group.
FG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-3 were included in this group.
Periods
Title
Milestones
Reasons Not Completed
Overall Study
Type
Comment
Milestone Data
STARTED
FG00022 subjects
FG0014 subjects
FG0023 subjects
Safety Population
Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
FG00022 subjects
FG0014 subjects
FG0023 subjects
COMPLETED
FG00021 subjects
FG0014 subjects
FG0023 subjects
NOT COMPLETED
FG0001 subjects
FG0010 subjects
FG0020 subjects
Type
Comment
Reasons
Withdrawal of Consent
FG0001 subjects
FG0010 subjects
FG0020 subjects
Baseline Characteristics Module
Baseline Analysis Population Description
Full Analysis Set (FAS) included all participants who received at least 1 dose of trial vaccine and for whom a valid pre-dose and at least one valid post-dose blood sample was taken.
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants who were flavivirus-naïve were included in this group.
BG001
TDV: DENV Immune: DENV-1 Positive
Denominators
Units
Counts
Participants
BG000
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Outcome Measures Module
Outcome Measures
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by microneutralization test 50% (MNT50).
Per Protocol Set (PPS) included all participants in the Full Analysis Set (FAS) who had no major protocol violations.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 15
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
Adverse Events Module
Frequency Threshold
5
Time Frame
All-Cause Mortality and Serious Adverse Events: From first vaccination through end of study (Day 360 [Month 12]); Non-serious (Other) AEs: Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose on Day 1 [Month 0] and Day 90 [Month 3]
Description
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants who were flavivirus-naïve were included in this group.
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
The magnitude of cellular immune response was assessed by the number of SFC/10^6 PBMCs. IFN-γ ELISpot response >3 times higher compared with baseline (no peptide) and ≥5 spots per 10^6 PBMCs was defined as cellular immune response. Cellular immune response to any peptide pool was reported. The peptide pools included prME, C, NS1, NS2, NS3, NS4 and NS5 for DENV-1, DENV-2, DENV-3 and DENV-4.
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
Phenotype characterization of cellular immune response was performed in a subset of participants with IFN- γ ELISPOT responses >50 SFC/10^6 cells and availability of sufficient cells. Markers included cluster of differentiation (CD) 4, CD8, IFN-γ, tumor necrosis factor-alpha (TNF-α) and interleukin-2 (IL-2). The peptide pools included C, NS1, NS2/4, NS3, NS5 for DENV-2 and prME for DENV-1, DENV-2, DENV-3 and DENV-4.
Days 15, 30 (Month 1), 90 (Month 3), 105, 120 (Month 4), and 360 (Month 12)
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
Phenotype characterization of cellular immune response was performed in a subset of participants with IFN- γ ELISPOT responses >50 SFC/10^6 cells and availability of sufficient cells. Markers included CD4, CD8, IFN-γ, tumor necrosis factor-alpha (TNF-α) and interleukin-2 (IL-2). The peptide pools included C, NS1, NS2/4, NS3, NS5 for DENV-2 and prME for DENV-1, DENV-2, DENV-3 and DENV-4.
Days 15, 30 (Month 1), 90 (Month 3), 105, 120 (Month 4), and 360 (Month 12)
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Vaccine viremia was assessed for each of the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Vaccine viral ribonucleic acid (RNA) was detected by a quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay. Percentages were rounded off to the nearest decimal place.
Duration of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
The duration of vaccine viremia for each vaccine strain was defined as the date when vaccine viremia was last detected (positive result) to date when vaccine viremia was first detected (positive result) + 1 day. It was assessed for each of the four vaccine strains: TDV-1, TDV-2, TDV-3 and TDV-4. Vaccine viral RNA was detected by qRT-PCR assay. Safety Analysis Set included all participants who received at least 1 dose of trial vaccine.
Up to Day 120 (Month 4)
Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Vaccine viremia was assessed for each of the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Vaccine viral RNA was detected by qRT-PCR assay.
Days 6, 9, 12, and 15
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included injection site pain [Grade 0 (no pain), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents daily activity with or without treatment)], injection site erythema [Grade 0 (<25 mm), 1 (25 - ≤ 50 mm), 2 (>50 - ≤ 100 mm), 3 (> 100 mm)] and injection site swelling [Grade 0 (<25 mm), 1 (25 - ≤ 50 mm), 2 (>50 - ≤ 100 mm), 3 (> 100 mm)]. Only categories for which there was at least 1 participant are reported.
Within 7 days after each of the vaccine dose given on Day 1 (Month 0) and 90 (Month 3)
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
Solicited systemic AEs were collected by participants using diary cards within 14 days after vaccination and will include fever, headache, asthenia, malaise and myalgia. Severity grades are: Grade 0: none, Grade 1: mild (no interference with daily activity), Grade 2: moderate (interference with daily activity with or without treatment), Grade 3: severe (prevents normal daily activity with or without treatment). A systemic AE of fever (defined as body temperature ≥ 100.4°F regardless of method taken) was derived from a daily temperature reading recorded within 14 days after vaccination. Only categories for which there was at least 1 participant are reported.
Within 14 days after each of the vaccine dose given on Day 1 (Month 0) and 90 (Month 3)
Percentage of Participants With at Least One Unsolicited Adverse Events (AEs) Following Each Vaccination
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a study vaccine; it does not necessarily have to have a causal relationship with study vaccine administration.
Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose given on Day 1 (Month 0) and 90 (Month 3)
Percentage of Participants With Serious Adverse Events (SAEs)
A SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or / significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the aforementioned criteria.
From first vaccination (Day 1) through end of study (Day 360 [Month 12])
Percentage of Participants With Medically Attended AEs (MAAEs)
MAAEs was defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.
From first vaccination (Day 1) through end of study (Day 360 [Month 12])
Portland
Oregon
97239
United States
Derived
Rauscher M, Youard Z, Faccin A, Patel SS, Pang H, Zent O. Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine. Expert Rev Vaccines. 2025 Dec;24(1):221-229. doi: 10.1080/14760584.2025.2480297. Epub 2025 Mar 27.
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-1 were included in this group.
BG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-3 were included in this group.
BG003
Total
Total of all reporting groups
21
BG0014
BG0023
BG00328
Full Range
years
Title
Denominators
Categories
Title
Measurements
BG00033.57(22.0 to 58.0)
BG00142.25(32.0 to 53.0)
BG00235.00(33.0 to 38.0)
BG00334.96(22 to 58)
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG00010
BG0012
BG0020
BG00312
Male
BG00011
BG0012
BG0023
BG00316
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0000
BG0010
BG0020
BG0030
Not Hispanic or Latino
BG00021
BG0013
BG0023
BG00327
Unknown or Not Reported
BG0000
BG0011
BG0020
BG0031
Race (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0010
BG0020
BG0030
Asian
BG0002
BG0011
BG0022
BG0035
Native Hawaiian or Other Pacific Islander
BG0001
BG0010
BG0020
BG0031
Black or African American
BG0001
BG0010
BG0020
BG0031
White
BG00017
BG0013
BG0021
BG00321
More than one race
BG0000
BG0010
BG0020
BG0030
Unknown or Not Reported
BG0000
BG0010
BG0020
BG0030
Region of Enrollment
Count of Participants
Participants
Title
Denominators
Categories
United States
Title
Measurements
BG00021
BG0014
BG0023
BG00328
Height
Mean
Full Range
centimeter (cm)
Title
Denominators
Categories
Title
Measurements
BG000169.18(148.6 to 182.1)
BG001175.01(163.6 to 188.0)
BG002174.33(172.7 to 176.3)
BG003170.56(148.6 to 188)
Weight
Mean
Full Range
kilogram (kg)
Title
Denominators
Categories
Title
Measurements
BG00071.54(48.7 to 101.2)
BG00171.86(64.9 to 78.0)
BG00279.15(68.0 to 97.8)
BG00372.4(48.7 to 101.2)
Body Mass Index (BMI)
BMI= weight (kg)/height (m^2)
Mean
Full Range
kilogram per meter square (kg/m^2)
Title
Denominators
Categories
Title
Measurements
BG00024.74(19.4 to 32.0)
BG00123.48(20.4 to 25.2)
BG00225.90(22.7 to 31.4)
BG00324.68(19.4 to 32)
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00021
OG0012
OG0023
Title
Denominators
Categories
DENV-1
Title
Measurements
OG00058.9(28.9 to 120.0)
OG00115325.2(32.4 to 7241076.9)
OG0025510.0(1271.4 to 23879.4)
DENV-2
Title
Measurements
OG00011.2(6.5 to 19.2)
OG0015200.2(13.9 to 1947484.8)
OG0024142.7(694.3 to 24718.0)
DENV-3
Title
Measurements
OG00042.1(16.2 to 109.8)
OG0012468.7(0.0 to 272077002.4)
OG0027244.0(5083.2 to 10323.3)
DENV-4
Title
Measurements
OG00019.7(10.6 to 36.7)
OG0011996.4(0.5 to 8424572.5)
OG0024909.2(2503.2 to 9628.0)
Primary
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 30 (Month 1)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
PPS included all participants in the FAS who had no major protocol violations.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 30 (Month 1)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00021
OG0012
OG0023
Title
Denominators
Categories
DENV-1
Title
Measurements
OG000336.1(168.8 to 669.3)
OG00145437.3(58.0 to 35607948.4)
OG00211091.9(706.7 to 174081.3)
DENV-2
Primary
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 60 (Month 2)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
PPS included all participants in the FAS who had no major protocol violations.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 60 (Month 2)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00021
OG0012
OG0023
Title
Denominators
Categories
DENV-1
Title
Measurements
OG000258.5(102.0 to 655.4)
OG00128109.0(65.7 to 12030804.9)
OG0027827.8(1701.7 to 36007.3)
DENV-2
Primary
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 90 (Month 3)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
PPS included all participants in the FAS who had no major protocol violations.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 90 (Month 3)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00021
OG0012
OG0023
Title
Denominators
Categories
DENV-1
Title
Measurements
OG000197.5(82.7 to 471.7)
OG00124989.5(244.4 to 2554755.6)
OG0028111.3(2866.7 to 22950.5)
DENV-2
Primary
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 105
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 105
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG0006
OG0011
OG0023
Title
Denominators
Categories
DENV-1
Title
Measurements
OG000326.0(117.8 to 902.2)
OG00113354.0(NA to NA)The 95% confidence interval (CI) was not estimable due to insufficient number of observations.
OG0026720.6
Primary
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 120 (Month 4)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 120 (Month 4)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00012
OG0012
OG0023
Title
Denominators
Categories
DENV-1
Title
Measurements
OG000433.8(149.0 to 1262.8)
OG00127123.8(5.1 to 144760235.6)
OG0029242.2(3693.4 to 23127.1)
DENV-2
Primary
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 150 (Month 5)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 150 (Month 5)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00015
OG0011
OG0023
Title
Denominators
Categories
DENV-1
Title
Measurements
OG000266.7(125.5 to 566.7)
OG00115703.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0027652.0(3152.7 to 18572.6)
Primary
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 180 (Month 6)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 180 (Month 6)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00015
OG0012
OG0023
Title
Denominators
Categories
DENV-1
Title
Measurements
OG000194.4(92.8 to 407.4)
OG00122880.8(2540.1 to 206105.7)
OG0024101.6(466.2 to 36082.4)
DENV-2
Primary
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 270 (Month 9)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 270 (Month 9)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00011
OG0011
OG0023
Title
Denominators
Categories
DENV-1
Title
Measurements
OG000121.7(23.4 to 631.8)
OG00116158.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0023913.9(982.7 to 15587.9)
Primary
GMT of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 360 (Month 12)
GMT of neutralizing antibodies were measured for each of the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
PPS included all participants in the FAS who had no major protocol violations. Overall number analyzed are the number of participants with data available for analyses.
Posted
Geometric Mean
95% Confidence Interval
titer
Day 360 (Month 12)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00011
OG0011
OG0022
Title
Denominators
Categories
DENV-1
Title
Measurements
OG000154.6(36.5 to 655.2)
OG00117546.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0022623.5(149.6 to 46022.7)
Secondary
Percentage of Participants With Interferon-gamma (IFN-γ) Enzyme-linked Immunospot (ELISpot) Responses to Tetravalent Dengue Vaccine (TDV)
IFN-γ ELISpot response >3 times higher compared with baseline (no peptide) and ≥5 spots per 10^6 peripheral blood mononuclear cells (PBMCs) was defined as cellular immune response. Cellular immune response to any peptide pool was reported. The peptide pools included pre-membrane envelope (prME), capsid (C), non-structural proteins (NS): NS1, NS2, NS3, NS4 and NS5 for DENV-1, DENV-2, DENV-3 and DENV-4.
PPS included all participants in the FAS who had no major protocol violations. Number analyzed is the number of participants with data available for analysis for the specified timepoint.
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00021
OG0012
OG0023
Title
Denominators
Categories
DENV-1 Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
Secondary
Magnitude of Cellular Immune Response Assessed by Number of Spot Forming Cells [SFC]/10^6 Peripheral Blood Mononuclear Cells (PBMCs) Measured by IFN-γ ELISpot Responses to TDV
The magnitude of cellular immune response was assessed by the number of SFC/10^6 PBMCs. IFN-γ ELISpot response >3 times higher compared with baseline (no peptide) and ≥5 spots per 10^6 PBMCs was defined as cellular immune response. Cellular immune response to any peptide pool was reported. The peptide pools included prME, C, NS1, NS2, NS3, NS4 and NS5 for DENV-1, DENV-2, DENV-3 and DENV-4.
PPS included all participants in the FAS who had no major protocol violations. Number analyzed is the number of participants with data available for analysis for the specified timepoint.
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00021
OG0012
OG0023
Title
Denominators
Categories
DENV-1 Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
Secondary
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD4+ T Cells by Intracellular Cytokine Staining (ICS)
Phenotype characterization of cellular immune response was performed in a subset of participants with IFN- γ ELISPOT responses >50 SFC/10^6 cells and availability of sufficient cells. Markers included cluster of differentiation (CD) 4, CD8, IFN-γ, tumor necrosis factor-alpha (TNF-α) and interleukin-2 (IL-2). The peptide pools included C, NS1, NS2/4, NS3, NS5 for DENV-2 and prME for DENV-1, DENV-2, DENV-3 and DENV-4.
Intracellular Cytokine Staining (ICS) Subset included participants from PPS (all participants in the FAS who had no major protocol violations) who had IFN-γ ELISPOT responses > 50 SFC/10^6 PBMCs and availability of sufficient cells for analysis. Number analyzed is the number of participants with data available for analysis for the specified timepoint.
Posted
Mean
Standard Deviation
percentage of CD4+ T cells
Days 15, 30 (Month 1), 90 (Month 3), 105, 120 (Month 4), and 360 (Month 12)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00021
OG0012
OG0023
Title
Denominators
Categories
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
Secondary
Phenotype Characterization of Cellular Immune Response to TDV Assessed as Percentage of Total CD8+ T Cells by Intracellular Cytokine Staining (ICS)
Phenotype characterization of cellular immune response was performed in a subset of participants with IFN- γ ELISPOT responses >50 SFC/10^6 cells and availability of sufficient cells. Markers included CD4, CD8, IFN-γ, tumor necrosis factor-alpha (TNF-α) and interleukin-2 (IL-2). The peptide pools included C, NS1, NS2/4, NS3, NS5 for DENV-2 and prME for DENV-1, DENV-2, DENV-3 and DENV-4.
ICS Subset included participants from PPS (all participants in the FAS who had no major protocol violations) who had IFN-γ ELISPOT responses >50 SFC/10^6 PBMCs and availability of sufficient cells for analysis. Number analyzed is the number of participants with data available for analysis for the specified timepoint.
Posted
Mean
Standard Deviation
percentage of CD8+ T cells
Days 15, 30 (Month 1), 90 (Month 3), 105, 120 (Month 4), and 360 (Month 12)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
Units
Counts
Participants
OG00021
OG0012
OG0023
Title
Denominators
Categories
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
Secondary
Percentage of Participants With Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Vaccine viremia was assessed for each of the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Vaccine viral ribonucleic acid (RNA) was detected by a quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay. Percentages were rounded off to the nearest decimal place.
Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Number analyzed is the number of participants with data available for analysis for the specified category.
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
OG003
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
Units
Counts
Participants
OG00022
OG0014
OG0023
OG003
Title
Denominators
Categories
Day 6: TDV-1
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG003
Secondary
Duration of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
The duration of vaccine viremia for each vaccine strain was defined as the date when vaccine viremia was last detected (positive result) to date when vaccine viremia was first detected (positive result) + 1 day. It was assessed for each of the four vaccine strains: TDV-1, TDV-2, TDV-3 and TDV-4. Vaccine viral RNA was detected by qRT-PCR assay. Safety Analysis Set included all participants who received at least 1 dose of trial vaccine.
Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Overall number analyzed=participants with data available for analyses. Number analyzed= participants with data available for analysis for the specified category.
Posted
Median
Full Range
days
Up to Day 120 (Month 4)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
OG003
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
Units
Counts
Participants
OG00014
OG0014
OG0023
OG003
Title
Denominators
Categories
TDV-2
ParticipantsOG00013
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG003
Secondary
Level of Vaccine Viremia for Each of the Four Vaccine Strains After Vaccination
Vaccine viremia was assessed for each of the four vaccine strain serotypes: TDV-1, TDV-2, TDV-3 and TDV-4. Vaccine viral RNA was detected by qRT-PCR assay.
Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Overall number analyzed=participants with data available for analyses. Number analyzed= participants with data available for analysis for the specified category.
Posted
Mean
Standard Deviation
log10 of genome equivalent per mL
Days 6, 9, 12, and 15
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
OG003
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
Units
Counts
Participants
OG00022
OG0014
OG0023
OG003
Title
Denominators
Categories
Day 6: TDV-1
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG003
Secondary
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination
Solicited local AEs (at injection site) were collected by participants using diary cards within 7 days after vaccination and included injection site pain [Grade 0 (no pain), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents daily activity with or without treatment)], injection site erythema [Grade 0 (<25 mm), 1 (25 - ≤ 50 mm), 2 (>50 - ≤ 100 mm), 3 (> 100 mm)] and injection site swelling [Grade 0 (<25 mm), 1 (25 - ≤ 50 mm), 2 (>50 - ≤ 100 mm), 3 (> 100 mm)]. Only categories for which there was at least 1 participant are reported.
Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Number analyzed is the number of participants with data available for analysis for the specified category.
Posted
Number
percentage of participants
Within 7 days after each of the vaccine dose given on Day 1 (Month 0) and 90 (Month 3)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
OG003
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
Units
Counts
Participants
OG00022
OG0014
OG0023
OG003
Title
Denominators
Categories
After First Vaccination: Any Solicited Local AEs
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG003
Secondary
Percentage of Participants With Solicited Systemic Reactions Following Each Vaccination
Solicited systemic AEs were collected by participants using diary cards within 14 days after vaccination and will include fever, headache, asthenia, malaise and myalgia. Severity grades are: Grade 0: none, Grade 1: mild (no interference with daily activity), Grade 2: moderate (interference with daily activity with or without treatment), Grade 3: severe (prevents normal daily activity with or without treatment). A systemic AE of fever (defined as body temperature ≥ 100.4°F regardless of method taken) was derived from a daily temperature reading recorded within 14 days after vaccination. Only categories for which there was at least 1 participant are reported.
Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Number analyzed is the number of participants with data available for analysis for the specified category.
Posted
Number
percentage of participants
Within 14 days after each of the vaccine dose given on Day 1 (Month 0) and 90 (Month 3)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
OG003
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
Units
Counts
Participants
OG00022
OG0014
OG0023
OG003
Title
Denominators
Categories
After First Vaccination: Any Solicited Systemic AE
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG003
Secondary
Percentage of Participants With at Least One Unsolicited Adverse Events (AEs) Following Each Vaccination
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a study vaccine; it does not necessarily have to have a causal relationship with study vaccine administration.
Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set. Number analyzed is the number of participants with data available for analysis for the specified category.
Posted
Number
percentage of participants
Up to 28 days (day of vaccination + 27 days) after administration of each vaccine dose given on Day 1 (Month 0) and 90 (Month 3)
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
OG003
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
Units
Counts
Participants
OG00022
OG0014
OG0023
OG003
Title
Denominators
Categories
After First Vaccination
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG003
Secondary
Percentage of Participants With Serious Adverse Events (SAEs)
A SAE is defined as any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or / significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the aforementioned criteria.
Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
Posted
Number
percentage of participants
From first vaccination (Day 1) through end of study (Day 360 [Month 12])
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
OG003
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
Units
Counts
Participants
OG00022
OG0014
OG0023
OG003
Title
Denominators
Categories
Title
Measurements
OG0004.5
OG00125.0
OG0020
OG003
Secondary
Percentage of Participants With Medically Attended AEs (MAAEs)
MAAEs was defined as AEs leading to a medical visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.
Safety Analysis Set included all participants who received at least one dose of trial vaccine. One participant was seropositive for all dengue strains at Screening and was therefore not allocated to dengue serotype 1 or 3 positive groups. The participant did receive two vaccine doses and was thus included in Safety Analysis Set.
Posted
Number
percentage of participants
From first vaccination (Day 1) through end of study (Day 360 [Month 12])
ID
Title
Description
OG000
TDV: Flavivirus-naïve
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants who were flavivirus-naïve were included in this group.
OG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-1 were included in this group.
OG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose). Participants with serology consistent with primary infection by DENV-3 were included in this group.
OG003
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
Units
Counts
Participants
OG00022
OG0014
OG0023
OG003
Title
Denominators
Categories
Title
Measurements
OG00045.5
OG00150.0
OG00233.3
OG003
0
22
1
22
22
22
EG001
TDV: DENV Immune: DENV-1 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-1 were included in this group.
0
4
1
4
4
4
EG002
TDV: DENV Immune: DENV-3 Positive
TDV 0.5 mL, SC injection, once on Day 1 (first dose) and then on Day 90 (second dose).
Participants with serology consistent with primary infection by DENV-3 were included in this group.
0
3
0
3
3
3
EG003
Unassigned Group
One participant did not meet the randomization criteria and was not allocated to any of the arm groups and was excluded from all analyses except safety analysis.
0
1
0
1
0
1
EG0001 affected22 at risk
EG0010 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Forearm fracture
Injury, poisoning and procedural complications
MedDRA 24
Systematic Assessment
EG0000 affected22 at risk
EG0011 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
EG0001 affected22 at risk
EG0011 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Asthenia
General disorders
MedDRA 24
Systematic Assessment
EG0009 affected22 at risk
EG0011 affected4 at risk
EG0022 affected3 at risk
EG0030 affected1 at risk
Back pain
Musculoskeletal and connective tissue disorders
MedDRA 24
Systematic Assessment
EG0001 affected22 at risk
EG0010 affected4 at risk
EG0021 affected3 at risk
EG0030 affected1 at risk
Contusion
Injury, poisoning and procedural complications
MedDRA 24
Systematic Assessment
EG0000 affected22 at risk
EG0010 affected4 at risk
EG0021 affected3 at risk
EG0030 affected1 at risk
Drug hypersensitivity
Immune system disorders
MedDRA 24
Systematic Assessment
EG0002 affected22 at risk
EG0010 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Erythema
Skin and subcutaneous tissue disorders
MedDRA 24
Systematic Assessment
EG00013 affected22 at risk
EG0011 affected4 at risk
EG0022 affected3 at risk
EG0030 affected1 at risk
Eye pain
Eye disorders
MedDRA 24
Systematic Assessment
EG0001 affected22 at risk
EG0011 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Headache
Nervous system disorders
MedDRA 24
Systematic Assessment
EG00014 affected22 at risk
EG0012 affected4 at risk
EG0022 affected3 at risk
EG0030 affected1 at risk
Injection site bruising
General disorders
MedDRA 24
Systematic Assessment
EG0001 affected22 at risk
EG0011 affected4 at risk
EG0021 affected3 at risk
EG0030 affected1 at risk
Injection site pruritus
General disorders
MedDRA 24
Systematic Assessment
EG0002 affected22 at risk
EG0010 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Malaise
General disorders
MedDRA 24
Systematic Assessment
EG00013 affected22 at risk
EG0011 affected4 at risk
EG0023 affected3 at risk
EG0030 affected1 at risk
Muscle strain
Injury, poisoning and procedural complications
MedDRA 24
Systematic Assessment
EG0002 affected22 at risk
EG0010 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Myalgia
Musculoskeletal and connective tissue disorders
MedDRA 24
Systematic Assessment
EG00011 affected22 at risk
EG0011 affected4 at risk
EG0023 affected3 at risk
EG0030 affected1 at risk
Nausea
Gastrointestinal disorders
MedDRA 24
Systematic Assessment
EG0002 affected22 at risk
EG0010 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Night sweats
Skin and subcutaneous tissue disorders
MedDRA 24
Systematic Assessment
EG0000 affected22 at risk
EG0011 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Oropharyngeal pain
Respiratory, thoracic and mediastinal disorders
MedDRA 24
Systematic Assessment
EG0001 affected22 at risk
EG0010 affected4 at risk
EG0021 affected3 at risk
EG0030 affected1 at risk
Pain
General disorders
MedDRA 24
Systematic Assessment
EG00015 affected22 at risk
EG0011 affected4 at risk
EG0022 affected3 at risk
EG0030 affected1 at risk
Rash erythematous
Skin and subcutaneous tissue disorders
MedDRA 24
Systematic Assessment
EG0000 affected22 at risk
EG0011 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Rash maculo-papular
Skin and subcutaneous tissue disorders
MedDRA 24
Systematic Assessment
EG0000 affected22 at risk
EG0011 affected4 at risk
EG0020 affected3 at risk
EG0030 affected1 at risk
Swelling
General disorders
MedDRA 24
Systematic Assessment
EG0008 affected22 at risk
EG0011 affected4 at risk
EG0021 affected3 at risk
EG0030 affected1 at risk
Viral upper respiratory tract infection
Infections and infestations
MedDRA 24
Systematic Assessment
EG0005 affected22 at risk
EG0010 affected4 at risk
EG0021 affected3 at risk
EG0030 affected1 at risk
OTHER
Results Disclosure Restriction on PI(s)?
Yes
Other Details
Not provided
D014777
Virus Diseases
D018177
Flavivirus Infections
D018178
Flaviviridae Infections
D012327
RNA Virus Infections
D006482
Hemorrhagic Fevers, Viral
Title
Measurements
OG00011557.1(6408.8 to 20841.2)
OG00112317.0(2677.3 to 56665.6)
OG00212221.9(1004.9 to 148651.5)
DENV-3
Title
Measurements
OG000344.7(146.3 to 812.6)
OG0017273.6(2983.8 to 17730.9)
OG00219062.2(3584.4 to 101373.6)
DENV-4
Title
Measurements
OG000141.1(69.1 to 288.0)
OG0015094.3(888.2 to 29218.2)
OG0025231.1(2064.2 to 13256.7)
Title
Measurements
OG0006293.0(3655.7 to 10833.1)
OG0019641.1(4219.1 to 22030.9)
OG0027236.5(432.9 to 120961.1)
DENV-3
Title
Measurements
OG000174.6(79.7 to 382.9)
OG0016174.2(200.8 to 189874.6)
OG00215536.5(3282.7 to 73532.6)
DENV-4
Title
Measurements
OG00078.2(35.0 to 174.7)
OG0016122.7(1974.7 to 18984.1)
OG0024254.8(720.8 to 25116.0)
Title
Measurements
OG0004077.0(2535.6 to 6555.5)
OG0019167.4(4646.6 to 18086.6)
OG0025450.5(857.1 to 34661.2)
DENV-3
Title
Measurements
OG000145.7(82.0 to 258.9)
OG0017043.3(1348.3 to 36792.6)
OG00210172.1(3690.3 to 28038.7)
DENV-4
Title
Measurements
OG00079.2(37.3 to 168.0)
OG0013240.2(9.6 to 1095309.8)
OG0024372.2(857.1 to 22304.5)
(3035.5 to 14879.7)
DENV-2
Title
Measurements
OG0003784.9(1419.9 to 10088.5)
OG0015810.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0025635.6(1094.4 to 29020.9)
DENV-3
Title
Measurements
OG000221.0(55.9 to 873.8)
OG0012360.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG00212835.4(3232.2 to 50971.0)
DENV-4
Title
Measurements
OG000211.6(73.5 to 609.2)
OG0012181.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0024011.8(1075.2 to 14969.0)
Title
Measurements
OG0003636.1(1912.1 to 6914.5)
OG0017424.1(1187.8 to 46402.4)
OG0026187.5(1220.4 to 31371.1)
DENV-3
Title
Measurements
OG000132.1(58.7 to 297.5)
OG0014179.0(16.5 to 1060298.0)
OG00210402.8(3725.1 to 29051.2)
DENV-4
Title
Measurements
OG000112.3(67.4 to 187.3)
OG0012428.6(16.2 to 364777.8)
OG0023835.1(619.1 to 23755.8)
DENV-2
Title
Measurements
OG0002415.2(1355.6 to 4303.0)
OG0017081.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0024589.6(586.8 to 35898.7)
DENV-3
Title
Measurements
OG000137.0(76.4 to 245.5)
OG0012829.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0028627.9(2944.9 to 25277.7)
DENV-4
Title
Measurements
OG000120.5(64.1 to 226.8)
OG0011729.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0023593.4(585.2 to 22065.1)
Title
Measurements
OG0001920.1(1070.8 to 3443.2)
OG00110697.4(138.0 to 829066.2)
OG0025458.3(622.8 to 47838.6)
DENV-3
Title
Measurements
OG00098.2(55.2 to 174.6)
OG0014198.3(601.5 to 29302.7)
OG0027495.0(3027.3 to 18556.1)
DENV-4
Title
Measurements
OG00076.1(37.9 to 152.8)
OG0012797.3(122.6 to 63824.0)
OG0022742.4(769.7 to 9770.8)
DENV-2
Title
Measurements
OG0001584.0(1038.1 to 2417.1)
OG0018585.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0023925.6(520.5 to 29606.8)
DENV-3
Title
Measurements
OG00085.6(44.3 to 165.2)
OG0013727.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0025985.8(5342.8 to 6706.1)
DENV-4
Title
Measurements
OG00039.5(16.8 to 92.9)
OG0011684.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0022021.3(400.1 to 10210.5)
DENV-2
Title
Measurements
OG0001287.8(581.0 to 2854.6)
OG0019623.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0021523.7(4.8 to 479413.6)
DENV-3
Title
Measurements
OG00077.0(48.2 to 122.9)
OG0014112.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0025287.8(613.1 to 45608.8)
DENV-4
Title
Measurements
OG00029.8(11.7 to 75.9)
OG0011171.0(NA to NA)The 95% CI was not estimable due to insufficient number of observations.
OG0021695.3(92.1 to 31197.8)
OG000100(83.9 to 100)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-1 Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG00095.2(83.2 to 100)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-1 Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000100(73.5 to 100)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-1 Day 180 (Month 6)
ParticipantsOG00015
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG00093.3(68.1 to 99.8)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-1 Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG00090.9(69.2 to 100)
OG001100(2.5 to 100)
OG002100(15.8 to 100)
DENV-2 Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000100(83.9 to 100)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-2 Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000100(83.9 to 100)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-2 Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000100(73.5 to 100)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-2 Day 180 (Month 6)
ParticipantsOG00015
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000100(78.2 to 100)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-2 Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG000100(71.5 to 100)
OG001100(2.5 to 100)
OG002100(15.8 to 100)
DENV-3 Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG00090.5(69.6 to 98.8)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-3 Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG00085.7(63.7 to 97.0)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-3 Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000100(73.5 to 100)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-3 Day 180 (Month 6)
ParticipantsOG00015
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG00073.3(44.9 to 92.2)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-3 Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG00090.9(58.7 to 99.8)
OG001100(2.5 to 100)
OG002100(15.8 to 100)
DENV-4 Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG00076.2(52.8 to 91.8)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-4 Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG00081.0(62.1 to 96.8)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-4 Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000100(73.5 to 100)
OG001100(15.8 to 100)
OG002100(29.2 to 100)
DENV-4 Day 180 (Month 6)
ParticipantsOG00015
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG00093.3(68.1 to 99.8)
OG00150.0(1.3 to 98.7)
OG002100(29.2 to 100)
DENV-4 Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG00054.5(42.1 to 99.6)
OG001100(2.5 to 100)
OG002100(15.8 to 100)
OG000232.3016± 407.55450
OG0012480.0000± 3486.03643
OG002301.6667± 159.39992
DENV-1 Day 90 (Month 3)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000189.5834± 350.89563
OG0011772.5000± 2485.48034
OG002235.0000± 109.65856
DENV-1 Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000209.8611± 329.52941
OG0011517.5000± 2138.99801
OG002116.6667± 76.53975
DENV-1 Day 180 (Month 6)
ParticipantsOG00014
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000162.5000± 237.01829
OG0011994.1665± 2806.03517
OG002242.7777± 166.35251
DENV-1 Day 360 (Month 12)
ParticipantsOG00010
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG000235.1667± 340.48572
OG0015.0000± NAStandard deviation (SD) was not estimable for a single participant.
OG002104.1665± 69.53193
DENV-2 Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0001156.9048± 1676.59869
OG0011847.5000± 2365.27218
OG002551.6667± 309.89245
DENV-2 Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000912.4603± 979.81060
OG0011462.5000± 1750.08928
OG002352.2223± 267.42243
DENV-2 Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000999.3056± 1416.74554
OG0011237.5000± 1566.24152
OG002161.6667± 150.52685
DENV-2 Day 180 (Month 6)
ParticipantsOG00015
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000965.1111± 1154.31464
OG0012070.0000± 2807.21392
OG002375.5557± 70.56015
DENV-2 Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG000974.0909± 1266.49305
OG001180.0000± NAStandard deviation (SD) was not estimable for a single participant.
OG002149.1665± 93.10263
DENV-3 Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000246.5789± 331.14209
OG0012035.0000± 2807.21392
OG002295.0000± 115.32563
DENV-3 Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000184.8148± 273.48687
OG001215.0000± 282.84271
OG002226.1113± 212.99673
DENV-3 Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000156.1112± 280.56878
OG0011565.0000± 2192.03102
OG002353.3333± 158.61379
DENV-3 Day 180 (Month 6)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000164.0909± 233.54441
OG0011726.6665± 2413.59091
OG002120.5553± 132.31197
DENV-3 Day 360 (Month 12)
ParticipantsOG00010
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG000137.6666± 194.74138
OG0015.0000± NAStandard deviation (SD) was not estimable for a single participant.
OG002123.3335± 16.49892
DENV-4 Day 30 (Month 1)
ParticipantsOG00016
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000224.0625± 420.90109
OG001395.0000± 473.76154
OG002153.3333± 219.10804
DENV-4 Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000153.0392± 290.81317
OG001362.5000± 477.29708
OG00271.6667± 38.11558
DENV-4 Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG000172.6388± 373.16791
OG00157.5000± 74.24621
OG002160.0000± 205.36553
DENV-4 Day 180 (Month 6)
ParticipantsOG00014
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG000162.2619± 378.98856
OG001573.3330± NAStandard deviation (SD) was not estimable for a single participant.
OG002155.0000± 165.86485
DENV-4 Day 360 (Month 12)
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG000215.0000± 325.02308
OG00140.0000± NAStandard deviation (SD) was not estimable for a single participant.
OG00275.8335± 62.46086
OG0000.0039595± 0.00434343
OG0010.0190000± 0.01272792
OG0020.0010800± 0.00175923
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040266± 0.00433388
OG0010.0235670± 0.03188062
OG0020.0042860± 0.00392989
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0022368± 0.00317381
OG0010.0023500± 0.00332340
OG0020.0013000± 0.00162631
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0013760± 0.00241658
OG0010.0024200± NASD was not estimable for a single participant.
OG0020.0005800± 0.00100459
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0027200± 0.00460175
OG0010.0108200± 0.00950352
OG0020.0039300± 0.00413312
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0023000± 0.00188396
OG0010.0025300± NASD was not estimable for a single participant.
OG0020.0019185± 0.00261842
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015836± 0.00205944
OG0010.0017250± 0.00023335
OG0020.0010800± 0.00175923
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0028357± 0.00490865
OG0010.0029000± 0.00410122
OG0020.0008220± 0.00084058
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0010256± 0.00147028
OG0010.0000000± 0.00000000
OG0020.0005700± 0.00098727
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0010760± 0.00089456
OG0010.0000600± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0018854± 0.00346501
OG0010.0006950± 0.00098288
OG0020.0009263± 0.00157941
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0005916± 0.00126206
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0024555± 0.00404542
OG0010.0196200± 0.02214658
OG0020.0061433± 0.00488514
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0023374± 0.00257822
OG0010.0230380± 0.03247317
OG0020.0075220± 0.00887617
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0006646± 0.00100992
OG0010.0077600± 0.01097430
OG0020.0049000± 0.00652393
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0036640± 0.00370999
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0069667± 0.01073570
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015773± 0.00239811
OG0010.0087700± 0.01240265
OG0020.0031500± 0.00279426
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0004526± 0.00059075
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0024485± 0.00167089
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0027775± 0.00490646
OG0010.0013760± 0.00084004
OG0020.0132000± 0.00930161
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0034686± 0.00432300
OG0010.0065550± 0.00927017
OG0020.0021460± 0.00082412
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0012968± 0.00161555
OG0010.0055000± 0.00777817
OG0020.0011827± 0.00198127
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0015260± 0.00124341
OG0010.0018300± NASD was not estimable for a single participant.
OG0020.0022467± 0.00267792
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015054± 0.00148462
OG0010.0013500± 0.00002828
OG0020.0000833± 0.00014434
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0009971± 0.00173995
OG0010.0000400± NASD was not estimable for a single participant.
OG0020.0003185± 0.00045043
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0007662± 0.00172488
OG0010.0030100± 0.00425678
OG0020.0029133± 0.00493389
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0035320± 0.00412765
OG0010.0050000± 0.00707107
OG0020.0050000± 0.00866025
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0057832± 0.02013270
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0037280± 0.00833606
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0063267± 0.01095811
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0017955± 0.00255443
OG0010.0041500± 0.00586899
OG0020.0049800± 0.00862561
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0025411± 0.00555028
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0480000± 0.02828427
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0007143± 0.00197846
OG0010.0010000± 0.00141421
OG0020.0009033± 0.00156462
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0059520± 0.00996730
OG0010.0145000± 0.02050610
OG0020.0050000± 0.00500000
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0070000± 0.01086278
OG0010.0060000± 0.00848528
OG0020.0043333± 0.00585947
FNg-, IL2+, TNFa-, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0046000± 0.00638749
OG0010.0100000± NASD was not estimable for a single participant.
OG0020.0040000± 0.00608276
FNg-, IL2+, TNFa-, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0057273± 0.00553337
OG0010.0000000± 0.00000000
OG0020.0030000± 0.00519615
FNg-, IL2+, TNFa-, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0095556± 0.01255101
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0205000± 0.01060660
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0098571± 0.02431930
OG0010.0250000± 0.03535534
OG0020.0376667± 0.01569501
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0063500± 0.01307177
OG0010.0000000± 0.00000000
OG0020.0466667± 0.08082904
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040542± 0.01131730
OG0010.0000000± 0.00000000
OG0020.0310000± 0.04293018
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0147960± 0.02254635
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0733333± 0.11846237
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0192727± 0.03854372
OG0010.0400000± 0.05656854
OG0020.0580000± 0.06009992
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0537778± 0.07350813
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0156338± 0.01341318
OG0010.0345000± 0.00070711
OG0020.0156567± 0.01987399
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0122825± 0.01207005
OG0010.0126170± 0.00213122
OG0020.0140527± 0.01124558
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0069514± 0.00806641
OG0010.0024950± 0.00133643
OG0020.0038167± 0.00109573
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0085950± 0.00881973
OG0010.0080000± NASD was not estimable for a single participant.
OG0020.0026967± 0.00223813
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0114250± 0.00754569
OG0010.0070200± 0.00021213
OG0020.0055467± 0.00026764
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0113109± 0.00863169
OG0010.0013000± NASD was not estimable for a single participant.
OG0020.0020875± 0.00290267
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0055626± 0.00618103
OG0010.0069450± 0.00426385
OG0020.0016633± 0.00144057
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0037906± 0.00471970
OG0010.0058220± 0.00022910
OG0020.0065793± 0.00473908
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0024256± 0.00231885
OG0010.0024550± 0.00338704
OG0020.0020033± 0.00186162
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0011180± 0.00155249
OG0010.0029100± NASD was not estimable for a single participant.
OG0020.0021767± 0.00293742
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0018340± 0.00213001
OG0010.0006150± 0.00086974
OG0020.0039667± 0.00308171
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0016511± 0.00156732
OG0010.0012900± NASD was not estimable for a single participant.
OG0020.0032340± 0.00314804
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0195281± 0.01605864
OG0010.0345000± 0.02757716
OG0020.0396233± 0.02896264
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0129087± 0.01001686
OG0010.0339320± 0.03984971
OG0020.0194627± 0.01535958
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0074276± 0.00487590
OG0010.0110000± 0.01555635
OG0020.0150933± 0.00694661
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0066833± 0.00676771
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0109133± 0.00335871
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0022
Title
Measurements
OG0000.0061417± 0.00294097
OG0010.0113650± 0.01014698
OG0020.0142633± 0.00845533
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0051673± 0.00437134
OG0010.0000200± NASD was not estimable for a single participant.
OG0020.0063440± 0.00014991
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0122905± 0.01136975
OG0010.0166300± 0.01466539
OG0020.0158833± 0.01526418
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0086183± 0.00744631
OG0010.0184670± 0.02212254
OG0020.0049393± 0.00441403
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0049071± 0.00312169
OG0010.0030300± 0.00428507
OG0020.0027600± 0.00079265
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0013000± 0.00209346
OG0010.0028600± NASD was not estimable for a single participant.
OG0020.0003333± 0.00057735
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0017842± 0.00228371
OG0010.0049750± 0.00504167
OG0020.0037833± 0.00366041
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0029951± 0.00407349
OG0010.0000500± NASD was not estimable for a single participant.
OG0020.0012250± 0.00173241
IFNg+, IL2+, TNFa+, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0184117± 0.02426237
OG0010.0855000± 0.01202082
OG0020.0023033± 0.00268712
IFNg+, IL2+, TNFa+, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0253419± 0.03739564
OG0010.0681170± 0.01978909
OG0020.0055893± 0.00486565
IFNg+, IL2+, TNFa+, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0180388± 0.01628354
OG0010.0261400± 0.01677257
OG0020.0015433± 0.00167828
IFNg+, IL2+, TNFa+, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0155460± 0.00736598
OG0010.0304700± NASD was not estimable for a single participant.
OG0020.0010267± 0.00177824
IFNg+, IL2+, TNFa+, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0255438± 0.02222056
OG0010.0345400± NASD was not estimable for a single participant.
OG0020.0046400± 0.00643170
IFNg+, IL2+, TNFa+, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0188425± 0.01749239
OG0010.0208000± NASD was not estimable for a single participant.
OG0020.0046440± 0.00532593
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0022795± 0.00242556
OG0010.0097000± 0.00608112
OG0020.0175233± 0.01552713
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0077111± 0.00670335
OG0010.0215985± 0.03042186
OG0020.0106660± 0.00795335
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0043389± 0.00329533
OG0010.0075000± 0.01060660
OG0020.0064033± 0.00380907
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0026940± 0.00293657
OG0010.0036000± NASD was not estimable for a single participant.
OG0020.0074700± 0.00868520
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0034200± 0.00296355
OG0010.0049350± 0.00509824
OG0020.0060967± 0.00653743
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0043200± 0.00603465
OG0010.0000300± NASD was not estimable for a single participant.
OG0020.0012700± 0.00179605
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0066462± 0.00792826
OG0010.0084785± 0.01063701
OG0020.0032200± 0.00404490
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0088740± 0.01159933
OG0010.0041720± 0.00065337
OG0020.0030600± 0.00204404
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0033060± 0.00441884
OG0010.0017200± 0.00243245
OG0020.0007633± 0.00085043
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0079900± 0.01211394
OG0010.0000390± NASD was not estimable for a single participant.
OG0020.0043500± 0.00284628
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0053583± 0.00565641
OG0010.0013750± 0.00194454
OG0020.0026010± 0.00178568
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0030009± 0.00444490
OG0010.0025000± NASD was not estimable for a single participant.
OG0020.0008885± 0.00125653
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015118± 0.00191718
OG0010.0015700± 0.00222032
OG0020.0004667± 0.00080829
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0021769± 0.00268205
OG0010.0047200± 0.00667509
OG0020.0005833± 0.00101036
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0010054± 0.00138756
OG0010.0000650± 0.00009192
OG0020.0005967± 0.00103346
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0016500± 0.00232157
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0005400± 0.00093531
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0006177± 0.00102890
OG0010.0000000± 0.00000000
OG0020.0008543± 0.00093306
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0006709± 0.00088977
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0010335± 0.00146159
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0063455± 0.00700260
OG0010.0061800± 0.00004243
OG0020.0146700± 0.01675231
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0099232± 0.01006738
OG0010.0043520± 0.00203364
OG0020.0085767± 0.00753694
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0041648± 0.00370931
OG0010.0016750± 0.00013435
OG0020.0016000± 0.00277128
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0062433± 0.00940730
OG0010.0005200± NASD was not estimable for a single participant.
OG0020.0040567± 0.00418584
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0036216± 0.00439516
OG0010.0012550± 0.00177484
OG0020.0052677± 0.00341188
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0016830± 0.00264616
OG0010.0012200± NASD was not estimable for a single participant.
OG0020.0016115± 0.00102601
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0039528± 0.00428498
OG0010.0011750± 0.00166170
OG0020.0062000± 0.00507572
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0043484± 0.00418555
OG0010.0027520± 0.00121340
OG0020.0020900± 0.00092677
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0019436± 0.00233770
OG0010.0007700± 0.00108894
OG0020.0001920± 0.00033255
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0012450± 0.00195501
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0014041± 0.00169202
OG0010.0014300± 0.00202233
OG0020.0001777± 0.00030773
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0009221± 0.00118263
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0003085± 0.00043628
IFNg+, IL2+, TNFa-, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0063457± 0.00739280
OG0010.0276900± 0.03013689
OG0020.0023867± 0.00266356
IFNg+, IL2+, TNFa-, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0136346± 0.01827227
OG0010.0124520± 0.00519299
OG0020.0025633± 0.00102627
IFNg+, IL2+, TNFa-, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0102555± 0.00890732
OG0010.0107550± 0.00034648
OG0020.0009733± 0.00168586
IFNg+, IL2+, TNFa-, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0086980± 0.00422567
OG0010.0081900± NASD was not estimable for a single participant.
OG0020.0015767± 0.00273087
IFNg+, IL2+, TNFa-, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0096186± 0.00919641
OG0010.0014200± NASD was not estimable for a single participant.
OG0020.0006143± 0.00065878
IFNg+, IL2+, TNFa-, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0051619± 0.00721208
OG0010.0130000± NASD was not estimable for a single participant.
OG0020.0013275± 0.00066397
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0012506± 0.00145149
OG0010.0034600± 0.00052326
OG0020.0049867± 0.00557140
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0041405± 0.00370046
OG0010.0030320± 0.00143967
OG0020.0044700± 0.00201167
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0023277± 0.00290426
OG0010.0029050± 0.00410829
OG0020.0034137± 0.00278951
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0025060± 0.00269757
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0020167± 0.00116453
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0019454± 0.00182333
OG0010.0014450± 0.00204354
OG0020.0012343± 0.00133427
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0007733± 0.00127164
OG0010.0012300± NASD was not estimable for a single participant.
OG0020.0004275± 0.00058336
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0060766± 0.00449815
OG0010.0428850± 0.01611496
OG0020.0240633± 0.03025849
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0037728± 0.00410557
OG0010.0185620± 0.01051892
OG0020.0079800± 0.00575490
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015660± 0.00222761
OG0010.0032600± 0.00217789
OG0020.0057033± 0.00286514
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0043250± 0.00738836
OG0010.0045900± NASD was not estimable for a single participant.
OG0020.0056000± 0.00592666
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0046358± 0.00481391
OG0010.0035500± 0.00308299
OG0020.0027843± 0.00263947
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0039912± 0.00426930
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0016035± 0.00145169
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020367± 0.00200211
OG0010.0119550± 0.01460176
OG0020.0034600± 0.00072547
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009933± 0.00141721
OG0010.0047720± 0.00660155
OG0020.0009560± 0.00076228
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0005400± 0.00102516
OG0010.0018050± 0.00255266
OG0020.0002240± 0.00038798
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0026620± 0.00525083
OG0010.0000430± NASD was not estimable for a single participant.
OG0020.0018267± 0.00165908
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0005960± 0.00082714
OG0010.0006150± 0.00086974
OG0020.0015343± 0.00028065
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0009544± 0.00127228
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0010335± 0.00146159
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0090109± 0.00856650
OG0010.0543850± 0.05359162
OG0020.0473333± 0.03165965
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0064879± 0.00601416
OG0010.0269820± 0.03538079
OG0020.0190567± 0.01080034
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0026280± 0.00337824
OG0010.0067600± 0.00956008
OG0020.0078667± 0.00525903
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0031033± 0.00107483
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0076500± 0.00526430
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0028733± 0.00244337
OG0010.0062700± 0.00886712
OG0020.0048743± 0.00332532
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0019966± 0.00189583
OG0010.0000200± NASD was not estimable for a single participant.
OG0020.0022035± 0.00064559
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0063809± 0.00759632
OG0010.0236700± 0.03338958
OG0020.0097900± 0.01084422
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0031547± 0.00278886
OG0010.0170245± 0.02400698
OG0020.0018733± 0.00038760
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0013470± 0.00190419
OG0010.0007900± 0.00111723
OG0020.0001920± 0.00033255
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0014450± 0.00172311
OG0010.0017300± NASD was not estimable for a single participant.
OG0020.0013200± 0.00117235
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009200± 0.00124907
OG0010.0062700± 0.00886712
OG0020.0031343± 0.00307798
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0032012± 0.00384132
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0003085± 0.00043628
IFNg+, IL2-, TNFa+, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0043954± 0.00510405
OG0010.0878850± 0.01328654
OG0020.0024367± 0.00211519
IFNg+, IL2-, TNFa+, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0079454± 0.00902785
OG0010.0505620± 0.00486207
OG0020.0035200± 0.00305210
IFNg+, IL2-, TNFa+, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0054914± 0.00581130
OG0010.0224000± 0.00582656
OG0020.0014500± 0.00146010
IFNg+, IL2-, TNFa+, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0114020± 0.01790945
OG0010.0284700± NASD was not estimable for a single participant.
OG0020.0016133± 0.00163026
IFNg+, IL2-, TNFa+, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0070050± 0.00365273
OG0010.0165400± NASD was not estimable for a single participant.
OG0020.0032910± 0.00127837
IFNg+, IL2-, TNFa+, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0065866± 0.00631099
OG0010.0188000± NASD was not estimable for a single participant.
OG0020.0022325± 0.00194384
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0024265± 0.00372846
OG0010.0270400± 0.03710896
OG0020.0520867± 0.05471529
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0045850± 0.00682112
OG0010.0245000± 0.03464823
OG0020.0250400± 0.03055440
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015112± 0.00306508
OG0010.0077600± 0.01097430
OG0020.0107867± 0.01190998
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0011860± 0.00163110
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0098533± 0.00613096
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0013082± 0.00189986
OG0010.0134350± 0.01711906
OG0020.0126110± 0.01695829
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0036009± 0.00879474
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0004275± 0.00058336
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0075520± 0.00844484
OG0010.0330950± 0.02107885
OG0020.0096033± 0.00523661
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0080525± 0.01055229
OG0010.0055700± 0.00255973
OG0020.0057660± 0.00370940
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0034662± 0.00388476
OG0010.0030950± 0.00437699
OG0020.0020620± 0.00178653
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0063400± 0.00932154
OG0010.0017500± NASD was not estimable for a single participant.
OG0020.0036733± 0.00290569
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0051208± 0.00397179
OG0010.0021100± 0.00104652
OG0020.0010100± 0.00156272
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0024600± 0.00277472
OG0010.0013000± NASD was not estimable for a single participant.
OG0020.0029585± 0.00170908
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020206± 0.00260390
OG0010.0042250± 0.00290621
OG0020.0026533± 0.00089891
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020286± 0.00206735
OG0010.0000000± 0.00000000
OG0020.0014793± 0.00041333
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009626± 0.00123421
OG0010.0016200± 0.00229103
OG0020.0013687± 0.00170601
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0003300± 0.00056303
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0005433± 0.00094108
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004290± 0.00077370
OG0010.0000000± 0.00000000
OG0020.0004800± 0.00083138
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0009997± 0.00125950
OG0010.0000400± NASD was not estimable for a single participant.
OG0020.0003635± 0.00051407
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0101574± 0.01135027
OG0010.0455950± 0.00084146
OG0020.0346667± 0.01833939
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0079673± 0.00830325
OG0010.0056000± 0.00637810
OG0020.0117927± 0.00809815
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0039573± 0.00329832
OG0010.0031250± 0.00427800
OG0020.0057620± 0.00888965
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0045767± 0.00294576
OG0010.0005200± NASD was not estimable for a single participant.
OG0020.0025567± 0.00157912
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0035933± 0.00301672
OG0010.0031800± 0.00055154
OG0020.0034733± 0.00388177
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0016788± 0.00208657
OG0010.0012300± NASD was not estimable for a single participant.
OG0020.0029385± 0.00085065
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0044780± 0.00694930
OG0010.0130950± 0.00154856
OG0020.0065773± 0.00619340
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0044494± 0.00362591
OG0010.0060550± 0.00856306
OG0020.0013160± 0.00044863
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0022088± 0.00270445
OG0010.0037850± 0.00535280
OG0020.0002120± 0.00036719
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0006333± 0.00098508
OG0010.0011700± NASD was not estimable for a single participant.
OG0020.0005267± 0.00091221
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015674± 0.00117213
OG0010.0000000± 0.00000000
OG0020.0011733± 0.00203227
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0006924± 0.00099937
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0004310± 0.00060953
IFNg+, IL2-, TNFa-, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0066937± 0.00722100
OG0010.0915950± 0.08259714
OG0020.0062000± 0.00563205
IFNg+, IL2-, TNFa-, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0079714± 0.00798185
OG0010.0441800± 0.02979748
OG0020.0015410± 0.00085791
IFNg+, IL2-, TNFa-, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0074104± 0.00838499
OG0010.0197800± 0.01241680
OG0020.0011100± 0.00192258
IFNg+, IL2-, TNFa-, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0086560± 0.01075630
OG0010.0087000± NASD was not estimable for a single participant.
OG0020.0010400± 0.00180133
IFNg+, IL2-, TNFa-, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0060286± 0.00431794
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0003600± 0.00062354
IFNg+, IL2-, TNFa-, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0032638± 0.00481301
OG0010.0138000± NASD was not estimable for a single participant.
OG0020.0005985± 0.00084641
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0019264± 0.00178363
OG0010.0039900± 0.00127279
OG0020.0442107± 0.04821126
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0044725± 0.00358891
OG0010.0075900± 0.00639225
OG0020.0092893± 0.00950700
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0014555± 0.00277488
OG0010.0029200± 0.00412950
OG0020.0020720± 0.00091517
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0019320± 0.00391432
OG0010.0006500± NASD was not estimable for a single participant.
OG0020.0022200± 0.00384515
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0018336± 0.00149423
OG0010.0006650± 0.00094045
OG0020.0021167± 0.00171704
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0007334± 0.00095378
OG0010.0000300± NASD was not estimable for a single participant.
OG0020.0004200± 0.00059397
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0024433± 0.00478745
OG0010.0000000± 0.00000000
OG0020.0064967± 0.00809850
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0087252± 0.01274292
OG0010.0000000± 0.00000000
OG0020.0004767± 0.00082561
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0022710± 0.00378206
OG0010.0000000± 0.00000000
OG0020.0303333± 0.05253887
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0032733± 0.00561714
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0096600± 0.01002032
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0054000± 0.00546757
OG0010.0014550± 0.00205768
OG0020.0101467± 0.01719490
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0057482± 0.01145463
OG0010.0010000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0023484± 0.00373999
OG0010.0000000± 0.00000000
OG0020.0019433± 0.00336595
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0027084± 0.00347026
OG0010.0115000± 0.00636396
OG0020.0010000± 0.00173205
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004250± 0.00128026
OG0010.0000000± 0.00000000
OG0020.0060000± 0.01039230
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0034460± 0.00473493
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0003333± 0.00057735
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040230± 0.00533216
OG0010.0051500± 0.00728320
OG0020.0026467± 0.00458416
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0028144± 0.00395317
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0175000± 0.00070711
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020638± 0.00335443
OG0010.0000000± 0.00000000
OG0020.0045367± 0.00785774
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0061967± 0.01073863
OG0010.0030000± 0.00424264
OG0020.0050000± 0.00866025
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0028243± 0.00657932
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0043583± 0.00586855
OG0010.0010000± NASD was not estimable for a single participant.
OG0020.0016667± 0.00152753
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0041158± 0.00481914
OG0010.0056500± 0.00799031
OG0020.0109800± 0.00962191
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0043409± 0.00775431
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0029114± 0.00457042
OG0010.0040100± 0.00567100
OG0020.0095367± 0.01244163
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0060424± 0.00716413
OG0010.0000000± 0.00000000
OG0020.0081633± 0.00851998
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0029867± 0.00872447
OG0010.0025000± 0.00353553
OG0020.0134067± 0.02049576
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0023333± 0.00297921
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0031367± 0.00432011
OG0010.0015750± 0.00222739
OG0020.0053133± 0.00920296
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0074518± 0.01318948
OG0010.0010000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0077311± 0.01847127
OG0010.0080100± 0.00425678
OG0020.0044800± 0.00577678
IFNg-, IL2+, TNFa+, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0105571± 0.00966628
OG0010.0120000± 0.00989949
OG0020.0074967± 0.00705266
IFNg-, IL2+, TNFa+, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0085371± 0.01020675
OG0010.0090000± 0.00282843
OG0020.0017500± 0.00303109
IFNg-, IL2+, TNFa+, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0227280± 0.03716463
OG0010.0050000± NASD was not estimable for a single participant.
OG0020.0069933± 0.00607619
IFNg-, IL2+, TNFa+, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0100288± 0.01429998
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0099800± 0.01728587
IFNg-, IL2+, TNFa+, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0138388± 0.01736932
OG0010.0020000± NASD was not estimable for a single participant.
OG0020.0485000± 0.03181981
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0006881± 0.00163780
OG0010.0000000± 0.00000000
OG0020.0222033± 0.03371578
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0083430± 0.01049993
OG0010.0000000± 0.00000000
OG0020.0081633± 0.00851998
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0039411± 0.00506722
OG0010.0075000± 0.01060660
OG0020.0193333± 0.03348632
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0057280± 0.00796431
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0019900± 0.00262874
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0058000± 0.00727803
OG0010.0031500± 0.00445477
OG0020.0023100± 0.00400104
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0055411± 0.00703655
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0770000± 0.00989949
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0048771± 0.00581334
OG0010.0010000± 0.00141421
OG0020.0055700± 0.00649882
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0110019± 0.01406371
OG0010.0010000± 0.00141421
OG0020.0033333± 0.00577350
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0048095± 0.00757376
OG0010.0055000± 0.00212132
OG0020.0146667± 0.01616581
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0066667± 0.01114750
OG0010.0090000± NASD was not estimable for a single participant.
OG0020.0086667± 0.01078579
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0131667± 0.01259750
OG0010.0000000± 0.00000000
OG0020.0056667± 0.00550757
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0045455± 0.00706206
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0025000± 0.00353553
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0027368± 0.00646222
OG0010.0005000± 0.00070711
OG0020.0032367± 0.00302788
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0042653± 0.00817199
OG0010.0190000± 0.02687006
OG0020.0066667± 0.01154701
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0041111± 0.00669406
OG0010.0050000± 0.00707107
OG0020.0173333± 0.02746513
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0008000± 0.00130384
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0010000± 0.00173205
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0092000± 0.01536808
OG0010.0000000± 0.00000000
OG0020.0080000± 0.00608276
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0115556± 0.01326755
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0340000± 0.02404163
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0019248± 0.00358174
OG0010.0030000± 0.00424264
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0051448± 0.00695615
OG0010.0000000± 0.00000000
OG0020.0130000± 0.00556776
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0054286± 0.00796600
OG0010.0035000± 0.00494975
OG0020.0043333± 0.00585947
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0021667± 0.00325064
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0016667± 0.00288675
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0079167± 0.00674818
OG0010.0000000± 0.00000000
OG0020.0116667± 0.01386843
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0058182± 0.00726386
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0040000± 0.00565685
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0029248± 0.00608645
OG0010.0030000± 0.00424264
OG0020.0082367± 0.01120795
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0050019± 0.00532053
OG0010.0015000± 0.00212132
OG0020.0030000± 0.00300000
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040476± 0.00569628
OG0010.0080000± 0.01131371
OG0020.0063333± 0.00709460
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0020000± 0.00400000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0010000± 0.00173205
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040000± 0.00645262
OG0010.0000000± 0.00000000
OG0020.0003333± 0.00057735
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0063636± 0.00868646
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0155000± 0.02192031
IFNg-, IL2+, TNFa-, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0033889± 0.00726101
OG0010.0010000± 0.00141421
OG0020.0140067± 0.02424294
IFNg-, IL2+, TNFa-, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0105906± 0.01290502
OG0010.0075000± 0.01060660
OG0020.0056667± 0.00513160
IFNg-, IL2+, TNFa-, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0081765± 0.01052518
OG0010.0225000± 0.00494975
OG0020.0100000± 0.00916515
IFNg-, IL2+, TNFa-, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0106000± 0.01436315
OG0010.0270000± NASD was not estimable for a single participant.
OG0020.0026667± 0.00461880
IFNg-, IL2+, TNFa-, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0138750± 0.01167950
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0116667± 0.00776745
IFNg-, IL2+, TNFa-, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0388750± 0.04258584
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0360000± 0.01272792
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0018571± 0.00381164
OG0010.0005000± 0.00070711
OG0020.0094100± 0.01524580
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0100520± 0.00984572
OG0010.0000000± 0.00000000
OG0020.0060000± 0.00519615
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0052105± 0.00611536
OG0010.0050000± 0.00707107
OG0020.0113333± 0.01962991
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0048000± 0.00672309
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0010000± 0.00173205
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0063636± 0.00569689
OG0010.0000000± 0.00000000
OG0020.0026667± 0.00461880
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0035556± 0.00538774
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0595000± 0.01343503
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0007143± 0.00327327
OG0010.0000000± 0.00000000
OG0020.0210000± 0.03637307
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0033810± 0.00696043
OG0010.0000000± 0.00000000
OG0020.0233333± 0.04041452
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0038586± 0.01248055
OG0010.0000000± 0.00000000
OG0020.0100000± 0.01732051
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0009967± 0.00199200
OG0010.0200000± NASD was not estimable for a single participant.
OG0020.0133333± 0.02309401
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0070000± 0.01205291
OG0010.0000000± 0.00000000
OG0020.0053333± 0.00923760
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0233636± 0.04872838
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0050000± 0.00707107
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0330526± 0.05651693
OG0010.0450000± 0.06363961
OG0020.0976667± 0.05173329
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0089474± 0.01355021
OG0010.0000000± 0.00000000
OG0020.1373333± 0.08247020
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0102239± 0.02008526
OG0010.0600000± 0.08485281
OG0020.0596667± 0.06961561
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0501960± 0.10057640
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.1293333± 0.19110556
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0088000± 0.01360392
OG0010.0050000± 0.00707107
OG0020.0413333± 0.04006661
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0466667± 0.05889822
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0050000± 0.00707107
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020952± 0.00545807
OG0010.0000000± 0.00000000
OG0020.0176667± 0.01078579
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015714± 0.00413003
OG0010.0000000± 0.00000000
OG0020.0500000± 0.07000000
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0060967± 0.01538351
OG0010.0050000± 0.00707107
OG0020.0000000± 0.00000000
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0031633± 0.00681587
OG0010.0400000± NASD was not estimable for a single participant.
OG0020.0466667± 0.07234178
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0064167± 0.01195034
OG0010.0200000± 0.02828427
OG0020.0020000± 0.00346410
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0322727± 0.05355388
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0030952± 0.00770652
OG0010.0850000± 0.12020815
OG0020.0710000± 0.05179768
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0025714± 0.00517273
OG0010.0100000± 0.01414214
OG0020.0996667± 0.11571661
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0025252± 0.00822553
OG0010.0300000± 0.04242641
OG0020.0336667± 0.04147690
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0031633± 0.00567028
OG0010.0100000± NASD was not estimable for a single participant.
OG0020.0700000± 0.12124356
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0063333± 0.00867948
OG0010.0250000± 0.03535534
OG0020.0846667± 0.10346658
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0237273± 0.04557212
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2-, TNFa+, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0109444± 0.02263644
OG0010.0450000± 0.06363961
OG0020.1443333± 0.09152231
IFNg-, IL2-, TNFa+, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0254118± 0.05545388
OG0010.0850000± 0.12020815
OG0020.1506667± 0.07759725
IFNg-, IL2-, TNFa+, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0341782± 0.05499065
OG0010.0500000± 0.07071068
OG0020.0906667± 0.05138417
IFNg-, IL2-, TNFa+, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.1933960± 0.34758253
OG0010.0200000± NASD was not estimable for a single participant.
OG0020.1556667± 0.14424401
IFNg-, IL2-, TNFa+, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0088750± 0.01786807
OG0010.0200000± NASD was not estimable for a single participant.
OG0020.1313333± 0.16341767
IFNg-, IL2-, TNFa+, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0786250± 0.07674250
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0350000± 0.02121320
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0007143± 0.00327327
OG0010.0200000± 0.02828427
OG0020.0500000± 0.07810250
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0050500± 0.01240745
OG0010.0000000± 0.00000000
OG0020.0570000± 0.06408588
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0116332± 0.02395900
OG0010.0450000± 0.06363961
OG0020.0133333± 0.02309401
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0049960± 0.01117140
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0500000± 0.07000000
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040909± 0.00870005
OG0010.0200000± 0.02828427
OG0020.0346667± 0.03500476
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0546667± 0.07867655
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0045624± 0.00373863
OG0010.0132800± 0.01657458
OG0020.0156033± 0.01522844
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0037701± 0.00361243
OG0010.0224970± 0.02915118
OG0020.0166927± 0.02121306
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0019732± 0.00203413
OG0010.0073800± 0.00794788
OG0020.0066433± 0.00434298
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0010780± 0.00144028
OG0010.0005900± NASD was not estimable for a single participant.
OG0020.0065467± 0.00607425
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0029255± 0.00304491
OG0010.0072700± 0.01028133
OG0020.0087367± 0.01165157
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0024944± 0.00265027
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0065440± 0.00147927
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020067± 0.00349245
OG0010.0017650± 0.00249609
OG0020.0027067± 0.00204500
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0027715± 0.00491943
OG0010.0084820± 0.01063206
OG0020.0062267± 0.00469696
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009887± 0.00117522
OG0010.0008700± 0.00123037
OG0020.0009033± 0.00078932
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0011940± 0.00117362
OG0010.0000290± NASD was not estimable for a single participant.
OG0020.0009600± 0.00088386
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020154± 0.00212428
OG0010.0013950± 0.00007778
OG0020.0016910± 0.00108924
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0004596± 0.00090723
OG0010.0012300± NASD was not estimable for a single participant.
OG0020.0009050± 0.00127986
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0029003± 0.00272483
OG0010.0194500± 0.02521543
OG0020.0487733± 0.04944810
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0013431± 0.00157750
OG0010.0154820± 0.02053155
OG0020.0255367± 0.02610415
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009037± 0.00153323
OG0010.0057600± 0.00814587
OG0020.0140600± 0.01672199
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0024900± 0.00217522
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0164733± 0.01680245
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0007918± 0.00151918
OG0010.0057700± 0.00816001
OG0020.0145877± 0.01618069
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0014281± 0.00135883
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0019985± 0.00102036
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0023851± 0.00349970
OG0010.0054855± 0.00665317
OG0020.0347667± 0.03185692
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0019231± 0.00285971
OG0010.0025200± 0.00213546
OG0020.0119560± 0.00976035
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0012856± 0.00145620
OG0010.0023950± 0.00338704
OG0020.0028307± 0.00290989
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0004400± 0.00061192
OG0010.0005900± NASD was not estimable for a single participant.
OG0020.0047467± 0.00638064
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020605± 0.00152830
OG0010.0021700± 0.00306884
OG0020.0043733± 0.00330736
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0007457± 0.00106006
OG0010.0000300± NASD was not estimable for a single participant.
OG0020.0009135± 0.00126784
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0006690± 0.00177413
OG0010.0000000± 0.00000000
OG0020.0182233± 0.01991388
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0037725± 0.00540746
OG0010.0000000± 0.00000000
OG0020.0034967± 0.00303810
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0016332± 0.00284966
OG0010.0000000± 0.00000000
OG0020.0176733± 0.02887941
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0024340± 0.00417459
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0038967± 0.00400400
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0026618± 0.00395446
OG0010.0006850± 0.00096874
OG0020.0020133± 0.00348720
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0042078± 0.00647931
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0170000± 0.02404163
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0026390± 0.00478957
OG0010.0030000± 0.00424264
OG0020.0126667± 0.02193931
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0052020± 0.00685207
OG0010.0085000± 0.01202082
OG0020.0060000± 0.00871780
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0022105± 0.00432793
OG0010.0000000± 0.00000000
OG0020.0173333± 0.03002221
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0040000± 0.00616441
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0013333± 0.00230940
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0047273± 0.00864975
OG0010.0000000± 0.00000000
OG0020.0113333± 0.01001665
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0103333± 0.01298075
OG0010.0020000± NASD was not estimable for a single participant.
OG0020.0200000± 0.01272792
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0064286± 0.01567345
OG0010.0300000± 0.04242641
OG0020.0476667± 0.06368935
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0037000± 0.00877856
OG0010.0000000± 0.00000000
OG0020.0700000± 0.10440307
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040016± 0.01133985
OG0010.0150000± 0.02121320
OG0020.0370000± 0.03517101
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0123960± 0.01897351
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0433333± 0.07505553
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0055455± 0.00831100
OG0010.0200000± 0.02828427
OG0020.0580000± 0.05031898
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0488889± 0.08153595
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0250000± 0.03535534
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0042128± 0.00495148
OG0010.0280000± 0.01272792
OG0020.0013133± 0.00119605
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0041551± 0.00511084
OG0010.0273970± 0.03353525
OG0020.0045693± 0.00367278
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0018916± 0.00291470
OG0010.0120550± 0.01689278
OG0020.0010800± 0.00183608
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0007540± 0.00168600
OG0010.0064500± NASD was not estimable for a single participant.
OG0020.0004667± 0.00080829
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0028073± 0.00241349
OG0010.0101050± 0.01051468
OG0020.0018300± 0.00189834
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0034077± 0.00388535
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0009250± 0.00130815
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0010586± 0.00123430
OG0010.0072000± 0.00026870
OG0020.0002150± 0.00037239
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015226± 0.00145884
OG0010.0106670± 0.00471357
OG0020.0004867± 0.00084293
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0013921± 0.00146570
OG0010.0009150± 0.00129401
OG0020.0002013± 0.00034872
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0020120± 0.00343865
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0012300± 0.00111665
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0016538± 0.00147798
OG0010.0013500± 0.00002828
OG0020.0010277± 0.00133012
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0005131± 0.00105742
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000010± 0.00000141
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0019679± 0.00226430
OG0010.0298850± 0.02884289
OG0020.0026567± 0.00243097
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0014351± 0.00201558
OG0010.0349770± 0.04811579
OG0020.0028800± 0.00258519
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0005243± 0.00078972
OG0010.0102600± 0.01450983
OG0020.0006033± 0.00104500
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0021520± 0.00374127
OG0010.0012200± NASD was not estimable for a single participant.
OG0020.0014633± 0.00168138
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0010900± 0.00094653
OG0010.0082700± 0.01169555
OG0020.0021233± 0.00266215
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0009091± 0.00135131
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0003085± 0.00043628
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0021766± 0.00325195
OG0010.0180950± 0.00296278
OG0020.0010083± 0.00123090
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0019537± 0.00217059
OG0010.0150950± 0.02123442
OG0020.0018260± 0.00126872
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0011930± 0.00181994
OG0010.0050000± 0.00707107
OG0020.0021353± 0.00311525
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0013140± 0.00138036
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0015733± 0.00166677
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009293± 0.00129407
OG0010.0019950± 0.00094045
OG0020.0006533± 0.00106308
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0006534± 0.00095082
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000010± 0.00000141
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0010538± 0.00210085
OG0010.0035100± 0.00352139
OG0020.0018700± 0.00323894
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0053990± 0.00689308
OG0010.0010000± 0.00141421
OG0020.0051633± 0.00690000
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0027358± 0.00322179
OG0010.0010000± 0.00141421
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0014640± 0.00259932
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0043267± 0.00749401
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0057182± 0.00781389
OG0010.0013200± 0.00186676
OG0020.0043133± 0.00447823
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0034000± 0.00501189
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0120000± 0.01697056
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0048771± 0.00855424
OG0010.0030000± 0.00282843
OG0020.0032367± 0.00336125
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0055520± 0.00738344
OG0010.0030000± 0.00424264
OG0020.0073333± 0.01021437
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0032105± 0.00491685
OG0010.0060000± 0.00141421
OG0020.0070000± 0.01212436
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0006000± 0.00134164
OG0010.0100000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0093636± 0.01344078
OG0010.0000000± 0.00000000
OG0020.0040000± 0.00692820
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0072222± 0.01328324
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0145000± 0.02050610
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0128095± 0.02841939
OG0010.1150000± 0.16263456
OG0020.1576667± 0.05173329
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0137000± 0.02625202
OG0010.0250000± 0.03535534
OG0020.1056667± 0.10390541
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0117384± 0.01908793
OG0010.0750000± 0.10606602
OG0020.0540000± 0.03751000
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0123960± 0.01978191
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0733333± 0.08736895
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0190000± 0.02560078
OG0010.0400000± 0.05656854
OG0020.0880000± 0.07830709
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0607778± 0.06849777
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0600000± 0.08485281
OG0000.0056604± 0.01627332
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0047007± 0.01502896
OG0010.0000750± 0.00010607
OG0020.0008833± 0.00152998
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0014703± 0.00267161
OG0010.0026650± 0.00376888
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0013600± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0082836± 0.01892632
OG0010.0008700± 0.00123037
OG0020.0009333± 0.00161658
IFNg+, IL2+, TNFa+, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0016900± 0.00330848
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0024200± 0.00800006
OG0010.0000000± 0.00000000
OG0020.0025900± 0.00448601
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0055525± 0.02087829
OG0010.0000000± 0.00000000
OG0020.0003040± 0.00052654
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0011563± 0.00285872
OG0010.0000000± 0.00000000
OG0020.0009200± 0.00159349
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0014160± 0.00316627
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0004400± 0.00076210
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0039800± 0.01170301
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0144803± 0.02730440
OG0010.0025450± 0.00359917
OG0020.0023033± 0.00203952
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0370610± 0.11025384
OG0010.0332550± 0.03782314
OG0020.0102833± 0.01232115
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0241643± 0.03587491
OG0010.0205000± 0.02899138
OG0020.0075367± 0.01031316
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0077060± 0.00514342
OG0010.0013600± NASD was not estimable for a single participant.
OG0020.0043933± 0.00382467
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0602155± 0.15407711
OG0010.0198650± 0.02809335
OG0020.0059600± 0.00785521
IFNg+, IL2-, TNFa+, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0112811± 0.01654078
OG0010.0031000± NASD was not estimable for a single participant.
OG0020.0021250± 0.00300520
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0159699± 0.04359877
OG0010.0017000± 0.00240416
OG0020.0004900± 0.00084870
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0707734± 0.25211961
OG0010.0278700± 0.01820093
OG0020.0029790± 0.00433441
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0288527± 0.08127031
OG0010.0117600± 0.01066317
OG0020.0032033± 0.00444653
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0070820± 0.01452614
OG0010.0040800± NASD was not estimable for a single participant.
OG0020.0012633± 0.00114718
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0560967± 0.15418829
OG0010.0060000± 0.00848528
OG0020.0022283± 0.00320135
IFNg+, IL2-, TNFa-, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0019478± 0.00186916
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0003281± 0.00087119
OG0010.0008500± 0.00120208
OG0020.0016667± 0.00288675
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0014660± 0.00368403
OG0010.0070000± 0.00989949
OG0020.0015217± 0.00263560
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0018853± 0.00779198
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0008120± 0.00181569
OG0010.0018800± NASD was not estimable for a single participant.
OG0020.0038700± 0.00670304
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004069± 0.00077459
OG0010.0000000± 0.00000000
OG0020.0120000± 0.02078461
IFNg-, IL2+, TNFa+, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0017656± 0.00266025
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0312150± 0.02010305
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0030481± 0.00520443
OG0010.0000000± 0.00000000
OG0020.0043333± 0.00378594
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0029060± 0.00436453
OG0010.0000000± 0.00000000
OG0020.0023333± 0.00404145
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040816± 0.00613449
OG0010.0085000± 0.01202082
OG0020.0023333± 0.00404145
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0110000± NASD was not estimable for a single participant.
OG0020.0033333± 0.00305505
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020000± 0.00300000
OG0010.0000000± 0.00000000
OG0020.0010000± 0.00173205
IFNg-, IL2+, TNFa-, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0062678± 0.01052641
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0070000± 0.00848528
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0148095± 0.02511227
OG0010.0195000± 0.01767767
OG0020.0060000± 0.01039230
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0115435± 0.01646364
OG0010.0235000± 0.01343503
OG0020.0253333± 0.03106981
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0093311± 0.01492871
OG0010.0250000± 0.03535534
OG0020.0316667± 0.03102150
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0246000± 0.02815670
OG0010.0110000± NASD was not estimable for a single participant.
OG0020.0266667± 0.04532475
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0250255± 0.03675944
OG0010.0295000± 0.03323402
OG0020.0080000± 0.01385641
IFNg-, IL2-, TNFa+, DENV-1, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0386067± 0.03656897
OG0010.0030000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0042606± 0.00562943
OG0010.0025550± 0.00361332
OG0020.0019520± 0.00148274
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0194350± 0.06157246
OG0010.0088700± 0.01254407
OG0020.0116087± 0.01939586
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0105474± 0.02561865
OG0010.0055000± 0.00777817
OG0020.0080000± 0.01385641
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0006717± 0.00164524
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0016067± 0.00278283
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0090928± 0.01602139
OG0010.0000000± 0.00000000
OG0020.0134433± 0.02214271
IFNg+, IL2+, TNFa+, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0115891± 0.01525538
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0003415± 0.00048295
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0115911± 0.02556364
OG0010.0034050± 0.00481540
OG0020.0230000± 0.02523886
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0331987± 0.06119374
OG0010.0022800± 0.00322441
OG0020.0284400± 0.02579343
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0235620± 0.03383365
OG0010.0034850± 0.00492853
OG0020.0246667± 0.02247962
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0246240± 0.03733209
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0220000± 0.02029778
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0097230± 0.01765134
OG0010.0025150± 0.00355675
OG0020.0270000± 0.03044667
IFNg+, IL2+, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0127111± 0.01056931
OG0010.0030800± NASD was not estimable for a single participant.
OG0020.0370000± 0.05232590
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0173215± 0.02522769
OG0010.0258900± 0.03126826
OG0020.0195800± 0.02908452
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0598512± 0.09417635
OG0010.1423700± 0.17729995
OG0020.0307000± 0.04702863
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0582231± 0.09890918
OG0010.0672150± 0.08879140
OG0020.0477333± 0.07132611
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0113983± 0.01184397
OG0010.0036900± NASD was not estimable for a single participant.
OG0020.0410800± 0.06836592
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0652592± 0.11485350
OG0010.0815250± 0.11098041
OG0020.0249567± 0.03147802
IFNg+, IL2+, TNFa+, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0482255± 0.06448748
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0038600± 0.00397394
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0188293± 0.02998412
OG0010.0054950± 0.00047376
OG0020.0023870± 0.00145326
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0944508± 0.21411201
OG0010.0699200± 0.09591196
OG0020.0180433± 0.02775222
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0866393± 0.13212126
OG0010.0516100± 0.06701958
OG0020.0104300± 0.01696039
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0439383± 0.05779160
OG0010.0039700± NASD was not estimable for a single participant.
OG0020.0182000± 0.03014830
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1042408± 0.16997426
OG0010.0430000± 0.06081118
OG0020.0129300± 0.01662924
IFNg+, IL2+, TNFa+, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0624582± 0.07686613
OG0010.0062300± NASD was not estimable for a single participant.
OG0020.0005050± 0.00071418
IFNg+, IL2+, TNFa+, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0008767± 0.00230893
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009874± 0.00211314
OG0010.0000000± 0.00000000
OG0020.0007800± 0.00135100
IFNg+, IL2+, TNFa+, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009700± 0.00213416
OG0010.0008200± 0.00115966
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0180160± 0.04024029
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0042550± 0.00972955
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0023250± 0.00398039
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0032181± 0.01085890
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0056398± 0.01706862
OG0010.0012400± 0.00135765
OG0020.0008933± 0.00154730
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0021729± 0.00454334
OG0010.0000000± 0.00000000
OG0020.0002303± 0.00039895
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000094± 0.00002102
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0064197± 0.01469896
OG0010.0000000± 0.00000000
OG0020.0002230± 0.00038625
IFNg+, IL2+, TNFa+, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0016022± 0.00296454
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0015550± 0.00250835
OG0010.0000000± 0.00000000
OG0020.0012000± 0.00207846
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0085133± 0.03027644
OG0010.0000000± 0.00000000
OG0020.0016367± 0.00283479
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0036457± 0.01124294
OG0010.0000000± 0.00000000
OG0020.0009000± 0.00155885
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0010662± 0.00230033
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0008033± 0.00139141
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0041225± 0.00963517
OG0010.0000000± 0.00000000
OG0020.0018367± 0.00318120
IFNg+, IL2+, TNFa-, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0012100± 0.00158071
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0021547± 0.00463731
OG0010.0000000± 0.00000000
OG0020.0034367± 0.00324179
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0165321± 0.03349865
OG0010.0011350± 0.00160513
OG0020.0035200± 0.00304882
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0106266± 0.01670632
OG0010.0000000± 0.00000000
OG0020.0038233± 0.00332250
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0031980± 0.00289504
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0010800± 0.00187061
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0050200± 0.00831467
OG0010.0000000± 0.00000000
OG0020.0018300± 0.00316965
IFNg+, IL2+, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0022100± 0.00348368
OG0010.0030800± NASD was not estimable for a single participant.
OG0020.0035050± 0.00495682
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0041307± 0.00810849
OG0010.0025350± 0.00091217
OG0020.0033267± 0.00357693
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0233062± 0.04002720
OG0010.0185000± 0.00777817
OG0020.0058683± 0.00636956
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0169390± 0.03074260
OG0010.0085000± 0.01202082
OG0020.0062367± 0.00856318
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0045183± 0.00427166
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0046667± 0.00808290
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0146317± 0.02786861
OG0010.0055000± 0.00777817
OG0020.0018967± 0.00184717
IFNg+, IL2+, TNFa-, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0047727± 0.00882216
OG0010.0089800± NASD was not estimable for a single participant.
OG0020.0006650± 0.00094045
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0046910± 0.00688923
OG0010.0000000± 0.00000000
OG0020.0007403± 0.00074504
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0375398± 0.08260377
OG0010.0105000± 0.01484924
OG0020.0037760± 0.00368127
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0233700± 0.04004137
OG0010.0054650± 0.00176070
OG0020.0013300± 0.00135044
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0066317± 0.00614863
OG0010.0026400± NASD was not estimable for a single participant.
OG0020.0005333± 0.00092376
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0185150± 0.03662069
OG0010.0045000± 0.00636396
OG0020.0015990± 0.00101474
IFNg+, IL2+, TNFa-, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0123264± 0.02486600
OG0010.0031200± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004213± 0.00110644
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004506± 0.00101312
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009306± 0.00314498
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0032000± 0.00715542
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0010313± 0.00198803
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0003888± 0.00109955
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0033314± 0.01348231
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0037375± 0.01220309
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020895± 0.00598185
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0001374± 0.00030724
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0027273± 0.00904534
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0007944± 0.00238333
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0127219± 0.01763276
OG0010.0130000± 0.01838478
OG0020.0251227± 0.03459943
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1050295± 0.20473645
OG0010.0500000± 0.07071068
OG0020.0724367± 0.10037912
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0778682± 0.14369053
OG0010.0325000± 0.04596194
OG0020.0842333± 0.14123712
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0423867± 0.04081753
OG0010.0013300± NASD was not estimable for a single participant.
OG0020.0353100± 0.05329149
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0899900± 0.12840170
OG0010.0433650± 0.06132737
OG0020.1106733± 0.17709757
IFNg+, IL2-, TNFa+, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.1513091± 0.21942879
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0108285± 0.01438467
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0509037± 0.10340779
OG0010.0475000± 0.06717514
OG0020.2024327± 0.30965583
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1922011± 0.32578940
OG0010.0861200± 0.11862423
OG0020.2125000± 0.20614012
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1737812± 0.29061637
OG0010.1272350± 0.17361593
OG0020.2045333± 0.26081536
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.1034720± 0.10489211
OG0010.0026600± NASD was not estimable for a single participant.
OG0020.1804967± 0.22221367
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1805500± 0.26929623
OG0010.1188100± 0.16393564
OG0020.2122567± 0.28717008
IFNg+, IL2-, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.1934944± 0.22273972
OG0010.0030800± NASD was not estimable for a single participant.
OG0020.2921435± 0.39194010
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0559643± 0.06460712
OG0010.3345000± 0.38961584
OG0020.1204393± 0.09431396
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.3096533± 0.30258266
OG0011.7050000± 2.10010714
OG0020.4185000± 0.53648089
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.3367906± 0.39199700
OG0011.3950000± 1.81726443
OG0020.4077633± 0.53498698
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.1848933± 0.10624645
OG0010.1200000± NASD was not estimable for a single participant.
OG0020.2482033± 0.29841232
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.4698942± 0.59554812
OG0011.4208650± 1.91465424
OG0020.2656767± 0.28387658
IFNg+, IL2-, TNFa+, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.3919327± 0.07020651
OG0010.0840000± NASD was not estimable for a single participant.
OG0020.0696435± 0.07020651
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0577929± 0.07400744
OG0010.1345000± 0.16334167
OG0020.0337727± 0.01914939
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.4733376± 0.74274218
OG0010.8520000± 1.15682669
OG0020.1478333± 0.11273901
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.4983025± 0.59609158
OG0010.8565000± 1.19288914
OG0020.1278067± 0.11606138
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.3420600± 0.35216040
OG0010.0250000± NASD was not estimable for a single participant.
OG0020.0825367± 0.07078845
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.6520608± 1.02666427
OG0010.9169950± 1.28373115
OG0020.1260100± 0.08686409
IFNg+, IL2-, TNFa+, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.5487509± 0.61534681
OG0010.0370000± NASD was not estimable for a single participant.
OG0020.0216435± 0.00898945
IFNg+, IL2-, TNFa+, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0018039± 0.00272657
OG0010.0009250± 0.00130815
OG0020.0011667± 0.00202073
IFNg+, IL2-, TNFa+, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0043176± 0.00745474
OG0010.0086150± 0.00337290
OG0020.0041833± 0.00218836
IFNg+, IL2-, TNFa+, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0365866± 0.13503691
OG0010.0105000± 0.01484924
OG0020.0013533± 0.00117309
IFNg+, IL2-, TNFa+, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0321340± 0.06596445
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0021467± 0.00199362
IFNg+, IL2-, TNFa+, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0212825± 0.04543103
OG0010.0087300± NASD was not estimable for a single participant.
OG0020.0020933± 0.00313690
IFNg+, IL2-, TNFa+, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0078913± 0.01390167
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0025400± 0.00359210
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0084024± 0.02103704
OG0010.0042950± 0.00607405
OG0020.0026897± 0.00335374
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0400210± 0.12804631
OG0010.0171950± 0.01810900
OG0020.0093150± 0.01317661
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0304975± 0.07184977
OG0010.0080000± 0.01131371
OG0020.0027633± 0.00478623
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0108580± 0.01167522
OG0010.0027500± NASD was not estimable for a single participant.
OG0020.0049600± 0.00751799
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0512582± 0.13375503
OG0010.0078650± 0.01112279
OG0020.0045967± 0.00557157
IFNg+, IL2-, TNFa+, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0308133± 0.07834697
OG0010.0030300± NASD was not estimable for a single participant.
OG0020.0026885± 0.00176989
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0122389± 0.01635494
OG0010.0070000± 0.00989949
OG0020.0557333± 0.06982874
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1276062± 0.23983604
OG0010.0304150± 0.04005760
OG0020.0969917± 0.10487019
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0542124± 0.11503390
OG0010.0071500± 0.01011163
OG0020.0521167± 0.07641460
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0434533± 0.06315100
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0259533± 0.03276050
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0605858± 0.09889217
OG0010.0070000± 0.00989949
OG0020.0488133± 0.05397085
IFNg+, IL2-, TNFa-, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0296555± 0.03699595
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0032750± 0.00269408
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0444316± 0.07748289
OG0010.0130000± 0.01838478
OG0020.0280367± 0.03627084
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.3801521± 0.67068473
OG0010.0512350± 0.06293957
OG0020.0415883± 0.03264917
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1645845± 0.33473334
OG0010.0448850± 0.05715544
OG0020.0257167± 0.01956887
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.1067160± 0.18769742
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0320700± 0.03599368
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1580330± 0.28256426
OG0010.0249450± 0.03119048
OG0020.0141700± 0.01698637
IFNg+, IL2-, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0614767± 0.11059188
OG0010.0030800± NASD was not estimable for a single participant.
OG0020.0240000± 0.03394113
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0470239± 0.06626524
OG0010.1770000± 0.11737973
OG0020.1204000± 0.08449249
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.3655695± 0.32065242
OG0010.7938700± 0.68429552
OG0020.1697217± 0.15709417
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1878077± 0.16247089
OG0010.3366500± 0.37002898
OG0020.0923333± 0.09666609
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.2131617± 0.26290060
OG0010.0650000± NASD was not estimable for a single participant.
OG0020.0487367± 0.03451214
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.2064808± 0.20421574
OG0010.2475000± 0.27223611
OG0020.0493700± 0.03374277
IFNg+, IL2-, TNFa-, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0857582± 0.08578152
OG0010.0630000± NASD was not estimable for a single participant.
OG0020.0191600± 0.01674429
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0506306± 0.07605994
OG0010.0575000± 0.05727565
OG0020.0524000± 0.01247678
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.4990933± 0.64014167
OG0010.3928700± 0.50186197
OG0020.1050550± 0.03026614
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.2820981± 0.37844969
OG0010.1433750± 0.19081276
OG0020.0326667± 0.01106044
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.1576200± 0.17541417
OG0010.0092500± NASD was not estimable for a single participant.
OG0020.0218933± 0.02273292
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.2221475± 0.32806338
OG0010.1045000± 0.12091526
OG0020.0220367± 0.00571385
IFNg+, IL2-, TNFa-, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.1124982± 0.16603829
OG0010.0062300± NASD was not estimable for a single participant.
OG0020.0027100± 0.00186676
IFNg+, IL2-, TNFa-, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020544± 0.00530875
OG0010.0000000± 0.00000000
OG0020.0033700± 0.00583701
IFNg+, IL2-, TNFa-, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0057029± 0.01291375
OG0010.0010400± 0.00147078
OG0020.0006167± 0.00106810
IFNg+, IL2-, TNFa-, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0476683± 0.19290073
OG0010.0000000± 0.00000000
OG0020.0002203± 0.00038163
IFNg+, IL2-, TNFa-, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0042000± 0.00939149
OG0010.0011900± NASD was not estimable for a single participant.
OG0020.0004167± 0.00072169
IFNg+, IL2-, TNFa-, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0031775± 0.00663800
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0003180± 0.00033860
IFNg+, IL2-, TNFa-, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0023488± 0.00154967
OG0010.0062500± NASD was not estimable for a single participant.
OG0020.0005100± 0.00072125
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0178773± 0.06036485
OG0010.0035250± 0.00229810
OG0020.0024100± 0.00301442
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0834539± 0.27160793
OG0010.0172600± 0.01199253
OG0020.0023883± 0.00272227
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0340990± 0.08904184
OG0010.0061500± 0.00281428
OG0020.0009000± 0.00155885
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0072940± 0.00965853
OG0010.0055000± NASD was not estimable for a single participant.
OG0020.0006200± 0.00107387
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0588364± 0.17313721
OG0010.0000000± 0.00000000
OG0020.0005067± 0.00072507
IFNg+, IL2-, TNFa-, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0090167± 0.02159530
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0003586± 0.00095429
OG0010.0000000± 0.00000000
OG0020.0003867± 0.00066973
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0012376± 0.00387489
OG0010.0000400± 0.00005657
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0002343± 0.00074914
OG0010.0009350± 0.00132229
OG0020.0109367± 0.01894286
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0038700± 0.00670304
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0017572± 0.00350183
OG0010.0000000± 0.00000000
OG0020.0040167± 0.00695707
IFNg-, IL2+, TNFa+, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0005464± 0.00126041
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0008511± 0.00168955
OG0010.0008500± 0.00120208
OG0020.0033333± 0.00577350
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0005805± 0.00114013
OG0010.0023600± 0.00333754
OG0020.0004017± 0.00055503
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004906± 0.00099670
OG0010.0000000± 0.00000000
OG0020.0073200± 0.01007451
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0007740± 0.00154767
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0011780± 0.00287673
OG0010.0000000± 0.00000000
OG0020.0035633± 0.00463250
IFNg-, IL2+, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0023900± 0.00325169
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0102150± 0.00596091
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004690± 0.00108044
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0008031± 0.00199994
OG0010.0047450± 0.00671044
OG0020.0028333± 0.00490748
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0010852± 0.00176370
OG0010.0022150± 0.00313248
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0007067± 0.00122398
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0003138± 0.00073427
OG0010.0000000± 0.00000000
OG0020.0113500± 0.01026974
IFNg-, IL2+, TNFa+, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0009045± 0.00166618
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0010010± 0.00144763
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0012721± 0.00302348
OG0010.0000450± 0.00006364
OG0020.0000467± 0.00008083
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0018919± 0.00612723
OG0010.0016550± 0.00234052
OG0020.0059367± 0.01028261
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000050± 0.00001225
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0005142± 0.00121641
OG0010.0015450± 0.00218496
OG0020.0070000± 0.01212436
IFNg-, IL2+, TNFa+, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0016991± 0.00376328
OG0010.0000400± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0003723± 0.00107549
OG0010.0000000± 0.00000000
OG0020.0010000± 0.00173205
IFNg-, IL2+, TNFa+, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0008947± 0.00141229
OG0010.0065000± 0.00919239
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0001547± 0.00044269
OG0010.0000000± 0.00000000
OG0020.0061467± 0.00600538
IFNg-, IL2+, TNFa+, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0108000± 0.01819890
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0037833± 0.01041435
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0083333± 0.01443376
IFNg-, IL2+, TNFa+, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0074013± 0.01825981
OG0010.0000400± NASD was not estimable for a single participant.
OG0020.0277150± 0.01515330
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004090± 0.00081029
OG0010.0000000± 0.00000000
OG0020.0170000± 0.02944486
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004844± 0.00107834
OG0010.0000000± 0.00000000
OG0020.0002883± 0.00049941
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0003021± 0.00109132
OG0010.0007600± 0.00107480
OG0020.0118367± 0.01821354
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004136± 0.00137188
OG0010.0000000± 0.00000000
OG0020.0053333± 0.00923760
IFNg-, IL2+, TNFa+, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0011589± 0.00257448
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0377150± 0.01030255
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0028214± 0.00421069
OG0010.0020000± 0.00282843
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0046852± 0.00622110
OG0010.0000000± 0.00000000
OG0020.0040000± 0.00458258
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0014295± 0.00279758
OG0010.0040000± 0.00565685
OG0020.0023333± 0.00404145
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0010000± 0.00200000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0070000± 0.00888819
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0030000± 0.00441073
OG0010.0010000± 0.00141421
OG0020.0003333± 0.00057735
IFNg-, IL2+, TNFa-, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0044918± 0.00731866
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0060000± 0.00848528
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0058100± 0.00997299
OG0010.0025000± 0.00353553
OG0020.0053333± 0.00378594
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0049679± 0.00700541
OG0010.0015000± 0.00212132
OG0020.0020000± 0.00346410
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0030861± 0.00437015
OG0010.0010000± 0.00141421
OG0020.0046667± 0.00808290
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0053333± 0.00757188
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040000± 0.00418994
OG0010.0000000± 0.00000000
OG0020.0093333± 0.01137248
IFNg-, IL2+, TNFa-, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0084900± 0.00839871
OG0010.0060000± NASD was not estimable for a single participant.
OG0020.0120000± 0.00707107
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0031157± 0.00523026
OG0010.0010000± 0.00141421
OG0020.0010000± 0.00173205
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0031300± 0.00536305
OG0010.0000000± 0.00000000
OG0020.0070000± 0.00500000
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0029057± 0.00488854
OG0010.0075000± 0.01060660
OG0020.0013333± 0.00230940
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0010000± 0.00244949
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0013333± 0.00230940
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0011667± 0.00251661
OG0010.0000000± 0.00000000
OG0020.0036667± 0.00635085
IFNg-, IL2+, TNFa-, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0050373± 0.00755522
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0080000± 0.00000000
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020662± 0.00415237
OG0010.0025000± 0.00353553
OG0020.0050000± 0.00458258
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0043576± 0.00713583
OG0010.0000000± 0.00000000
OG0020.0060000± 0.00600000
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0020010± 0.00385930
OG0010.0035000± 0.00494975
OG0020.0023333± 0.00404145
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0016667± 0.00265832
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0053333± 0.00404145
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0040000± 0.00529150
OG0010.0040000± 0.00565685
OG0020.0066667± 0.01154701
IFNg-, IL2+, TNFa-, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0015591± 0.00239132
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0070000± 0.00848528
IFNg-, IL2+, TNFa-, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0152389± 0.04708044
OG0010.0090000± 0.01272792
OG0020.0033333± 0.00577350
IFNg-, IL2+, TNFa-, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0052506± 0.00585230
OG0010.0000000± 0.00000000
OG0020.0023333± 0.00208167
IFNg-, IL2+, TNFa-, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0044441± 0.00551617
OG0010.0195000± 0.01060660
OG0020.0043333± 0.00750555
IFNg-, IL2+, TNFa-, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0078000± 0.01744133
OG0010.0090000± NASD was not estimable for a single participant.
OG0020.0013333± 0.00115470
IFNg-, IL2+, TNFa-, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0076250± 0.01245492
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0023333± 0.00404145
IFNg-, IL2+, TNFa-, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0159263± 0.01687248
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0095000± 0.01060660
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0039386± 0.00920362
OG0010.0000000± 0.00000000
OG0020.0043333± 0.00585947
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0042890± 0.00519741
OG0010.0000000± 0.00000000
OG0020.0040000± 0.00692820
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0037368± 0.00647081
OG0010.0000000± 0.00000000
OG0020.0033333± 0.00577350
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0056667± 0.00737111
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0032727± 0.00392660
OG0010.0020000± 0.00282843
OG0020.0013333± 0.00230940
IFNg-, IL2+, TNFa-, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0063789± 0.00762607
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0045000± 0.00494975
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0058029± 0.01553300
OG0010.0060000± 0.00848528
OG0020.0126667± 0.02193931
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0103476± 0.01374186
OG0010.0090000± 0.00848528
OG0020.0400000± 0.06928203
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0141552± 0.02722292
OG0010.0070000± 0.00989949
OG0020.0426667± 0.06379133
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0141667± 0.02123598
OG0010.0270000± NASD was not estimable for a single participant.
OG0020.0533333± 0.06880649
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0327508± 0.05413463
OG0010.0385000± 0.01484924
OG0020.0526667± 0.09122134
IFNg-, IL2-, TNFa+, DENV-2, NS1, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0594618± 0.09358403
OG0010.0030000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 15
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0188947± 0.02597596
OG0010.1070000± 0.13293607
OG0020.2126667± 0.24855851
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 30 (Month 1)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0218395± 0.03032141
OG0010.0555000± 0.06010408
OG0020.2116667± 0.21159946
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 90 (Month 3)
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0217506± 0.03474512
OG0010.0770000± 0.10889444
OG0020.2006667± 0.22830097
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0232000± 0.01003494
OG0010.0150000± NASD was not estimable for a single participant.
OG0020.1756667± 0.14911181
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 120 (Month 4)
ParticipantsOG00010
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0698280± 0.11664297
OG0010.1095000± 0.13930004
OG0020.1763333± 0.25602799
IFNg-, IL2-, TNFa+, DENV-2, NS2/4, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0789200± 0.08581529
OG0010.0180000± NASD was not estimable for a single participant.
OG0020.2550000± 0.34648232
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0101905± 0.01632825
OG0010.0415000± 0.02616295
OG0020.0160000± 0.01969772
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0269048± 0.03805993
OG0010.3430000± 0.33234019
OG0020.1503333± 0.19894807
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0510614± 0.06214111
OG0010.3680000± 0.5176021
OG0020.1486667± 0.20771455
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0508333± 0.05468242
OG0010.1040000± NASD was not estimable for a single participant.
OG0020.1286667± 0.16850618
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0494400± 0.05523830
OG0010.5175000± 0.67952962
OG0020.1460000± 0.21915291
IFNg-, IL2-, TNFa+, DENV-2, NS3, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0526782± 0.05324075
OG0010.0530000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0088638± 0.01482118
OG0010.0350000± 0.02262742
OG0020.0426667± 0.05021288
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 30 (Month 1)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0344576± 0.03851547
OG0010.0780000± 0.05656854
OG0020.0683333± 0.08251263
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 90 (Month 3)
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0603471± 0.11313845
OG0010.0870000± 0.12303658
OG0020.0323333± 0.01778576
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 105
ParticipantsOG0006
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0643333± 0.09686004
OG0010.0410000± NASD was not estimable for a single participant.
OG0020.0390000± 0.00871780
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 120 (Month 4)
ParticipantsOG00012
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0471067± 0.06000386
OG0010.0940000± 0.11879394
OG0020.0090000± 0.01558846
IFNg-, IL2-, TNFa+, DENV-2, NS5, Day 360 (Month 12)
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0758600± 0.11250364
OG0010.0090000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2-, TNFa+, DENV-2, C, Day 15
ParticipantsOG00018
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0103350± 0.01602034
OG0010.0230000± 0.00000000
OG0020.0760000± 0.06919538
IFNg-, IL2-, TNFa+, DENV-2, C, Day 30 (Month 1)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0085812± 0.01180887
OG0010.0285000± 0.00777817
OG0020.0773333± 0.06971609
IFNg-, IL2-, TNFa+, DENV-2, C, Day 90 (Month 3)
ParticipantsOG00017
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0198388± 0.04371084
OG0010.0065000± 0.00919239
OG0020.0423333± 0.03516153
IFNg-, IL2-, TNFa+, DENV-2, C, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0380000± 0.05251190
OG0010.0100000± NASD was not estimable for a single participant.
OG0020.0653333± 0.06033517
IFNg-, IL2-, TNFa+, DENV-2, C, Day 120 (Month 4)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0123363± 0.01514560
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0233333± 0.01527525
IFNg-, IL2-, TNFa+, DENV-2, C, Day 360 (Month 12)
ParticipantsOG0008
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0363138± 0.05384733
OG0010.0440000± NASD was not estimable for a single participant.
OG0020.0050000± 0.00707107
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0054286± 0.00981311
OG0010.0110000± 0.00141421
OG0020.0326667± 0.04051337
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0054275± 0.00814845
OG0010.0130000± 0.00141421
OG0020.0266667± 0.04618802
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0091942± 0.01593313
OG0010.0165000± 0.02333452
OG0020.0060000± 0.01039230
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0174000± 0.01399286
OG0010.0080000± NASD was not estimable for a single participant.
OG0020.0080000± 0.01216553
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0141164± 0.02282460
OG0010.0350000± 0.03818377
OG0020.0000000± 0.00000000
IFNg-, IL2-, TNFa+, DENV-2, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0237878± 0.03150909
OG0010.0080000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0066860± 0.01511548
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0120563± 0.02306468
OG0010.0000650± 0.00009192
OG0020.0008400± 0.00145492
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0025821± 0.00448167
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0009780± 0.00177382
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0007567± 0.00131059
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0114040± 0.01887834
OG0010.0008900± 0.00125865
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0016822± 0.00344548
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0030476± 0.01094264
OG0010.0000000± 0.00000000
OG0020.0011667± 0.00202073
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0076840± 0.01657770
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0023789± 0.00539609
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0012082± 0.00231967
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0042031± 0.01075305
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0001489± 0.00044667
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0184242± 0.02939174
OG0010.0089250± 0.00717713
OG0020.0051230± 0.00771231
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0591005± 0.11403676
OG0010.0210900± 0.02391435
OG0020.0164220± 0.01587121
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0313922± 0.04328981
OG0010.0190000± 0.02687006
OG0020.0114300± 0.01150064
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0078900± 0.00938985
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0081933± 0.00716934
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0976318± 0.16524353
OG0010.0153650± 0.02172939
OG0020.0053067± 0.00378127
IFNg+, IL2-, TNFa+, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0295267± 0.04211372
OG0010.0029900± NASD was not estimable for a single participant.
OG0020.0051685± 0.00321239
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0220818± 0.05553037
OG0010.0025100± 0.00083439
OG0020.0020167± 0.00122676
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.1106415± 0.28502664
OG0010.0203700± 0.01466539
OG0020.0049517± 0.00371622
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0434985± 0.10671828
OG0010.0063250± 0.00279307
OG0020.0043667± 0.00583981
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0047020± 0.00507315
OG0010.0052300± NASD was not estimable for a single participant.
OG0020.0020467± 0.00354493
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0668900± 0.14991991
OG0010.0060000± 0.00848528
OG0020.0072167± 0.00913589
IFNg+, IL2-, TNFa-, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0047733± 0.00369270
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0007200± 0.00101823
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0001975± 0.00067344
OG0010.0015500± 0.00219203
OG0020.0064300± 0.00844954
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0006700± 0.00147478
OG0010.0011950± 0.00168999
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0004426± 0.00153225
OG0010.0000000± 0.00000000
OG0020.0106033± 0.01836551
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0001760± 0.00039355
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0006105± 0.00166994
OG0010.0014550± 0.00205768
OG0020.0050000± 0.00556776
IFNg-, IL2+, TNFa+, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0016056± 0.00247607
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0097150± 0.01373908
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0031952± 0.00507926
OG0010.0000000± 0.00000000
OG0020.0056667± 0.00550757
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0049365± 0.00709962
OG0010.0000000± 0.00000000
OG0020.0036667± 0.00404145
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0043447± 0.00780649
OG0010.0040000± 0.00000000
OG0020.0046667± 0.00568624
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0052000± 0.00589067
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0050000± 0.00624500
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0027273± 0.00405194
OG0010.0065000± 0.00919239
OG0020.0073333± 0.00945163
IFNg-, IL2+, TNFa-, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0067122± 0.00782834
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0045000± 0.00212132
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0090000± 0.01403916
OG0010.0255000± 0.00494975
OG0020.0260000± 0.04503332
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0099805± 0.01591483
OG0010.0205000± 0.01343503
OG0020.0383333± 0.04645787
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0107505± 0.01922024
OG0010.0205000± 0.02899138
OG0020.0056667± 0.00513160
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0202000± 0.02198181
OG0010.0070000± NASD was not estimable for a single participant.
OG0020.0130000± 0.01473092
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0142545± 0.01922025
OG0010.0440000± 0.06222540
OG0020.0120000± 0.02078461
IFNg-, IL2-, TNFa+, DENV-3, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0427178± 0.07626460
OG0010.0050000± NASD was not estimable for a single participant.
OG0020.0150000± 0.02121320
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0014671± 0.00263630
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0026483± 0.00397803
OG0010.0020800± 0.00294156
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0018358± 0.00385801
OG0010.0016100± 0.00227688
OG0020.0002253± 0.00039029
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0027000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0008555± 0.00283722
OG0010.0008400± 0.00118794
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa+, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0039322± 0.00916710
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0003738± 0.00092592
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0009323± 0.00205020
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0003679± 0.00110265
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0027000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0002582± 0.00058436
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg+, IL2+, TNFa-, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0002267± 0.00068000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0103743± 0.01256981
OG0010.0017750± 0.00019092
OG0020.0052593± 0.00613561
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0138195± 0.01653836
OG0010.0125800± 0.01190768
OG0020.0101350± 0.00905302
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0082212± 0.01488787
OG0010.0048250± 0.00682358
OG0020.0045720± 0.00505935
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0066820± 0.00839444
OG0010.0150000± NASD was not estimable for a single participant.
OG0020.0066967± 0.00634139
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0150073± 0.01487729
OG0010.0162450± 0.01058539
OG0020.0029540± 0.00453868
IFNg+, IL2-, TNFa+, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0149633± 0.02271217
OG0010.0058400± NASD was not estimable for a single participant.
OG0020.0170000± 0.02404163
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0059200± 0.01028071
OG0010.0036850± 0.00289207
OG0020.0002477± 0.00042897
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0154140± 0.02895635
OG0010.0261500± 0.02807214
OG0020.0023900± 0.00272666
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0076211± 0.01271810
OG0010.0046900± 0.00005657
OG0020.0020187± 0.00116433
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0061340± 0.00559455
OG0010.0081100± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0059764± 0.00713827
OG0010.0037600± 0.00294156
OG0020.0009700± 0.00149362
IFNg+, IL2-, TNFa-, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0034878± 0.00469261
OG0010.0029200± NASD was not estimable for a single participant.
OG0020.0004985± 0.00070499
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0006238± 0.00118351
OG0010.0016350± 0.00231224
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0003618± 0.00078989
OG0010.0000350± 0.00004950
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0005989± 0.00122750
OG0010.0000000± 0.00000000
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0000000± 0.00000000
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0012515± 0.00280308
OG0010.0014600± 0.00206475
OG0020.0053333± 0.00923760
IFNg-, IL2+, TNFa+, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0005133± 0.00152134
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0047150± 0.00666802
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0048171± 0.00860057
OG0010.0060000± 0.00848528
OG0020.0046667± 0.00416333
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0068115± 0.00782670
OG0010.0000000± 0.00000000
OG0020.0026667± 0.00461880
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0027321± 0.00433336
OG0010.0050000± 0.00707107
OG0020.0006667± 0.00115470
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0000000± 0.00000000
OG0010.0080000± NASD was not estimable for a single participant.
OG0020.0076667± 0.00929157
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0023636± 0.00273030
OG0010.0060000± 0.00848528
OG0020.0123333± 0.01721434
IFNg-, IL2+, TNFa-, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0080456± 0.00651373
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0050000± 0.00565685
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 15
ParticipantsOG00021
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0157619± 0.02615375
OG0010.0595000± 0.05868986
OG0020.1193333± 0.06900242
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 30 (Month 1)
ParticipantsOG00020
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0130950± 0.01958094
OG0010.0180000± 0.02545584
OG0020.0733333± 0.09451631
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 90 (Month 3)
ParticipantsOG00019
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0124347± 0.01836407
OG0010.0125000± 0.01767767
OG0020.0330000± 0.02868798
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 105
ParticipantsOG0005
ParticipantsOG0011
ParticipantsOG0023
Title
Measurements
OG0000.0238000± 0.02763512
OG0010.0240000± NASD was not estimable for a single participant.
OG0020.0176667± 0.01703917
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 120 (Month 4)
ParticipantsOG00011
ParticipantsOG0012
ParticipantsOG0023
Title
Measurements
OG0000.0106618± 0.01504292
OG0010.0300000± 0.03535534
OG0020.0293333± 0.05080682
IFNg-, IL2-, TNFa+, DENV-4, prME, Day 360 (Month 12)
ParticipantsOG0009
ParticipantsOG0011
ParticipantsOG0022
Title
Measurements
OG0000.0337200± 0.04946269
OG0010.0000000± NASD was not estimable for a single participant.
OG0020.0800000± 0.11313708
1
1
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0030.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
Day 6: TDV-2
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG00233.3(0.8 to 90.6)
OG003
Day 6: TDV-3
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 6: TDV-4
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 9: TDV-1
ParticipantsOG00021
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 9: TDV-2
ParticipantsOG00021
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00019.0(5.4 to 41.9)
OG00175.0(19.4 to 99.4)
OG00266.7(9.4 to 99.2)
OG003
Day 9: TDV-3
ParticipantsOG00021
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 9: TDV-4
ParticipantsOG00021
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0004.8(0.1 to 23.8)
OG00125.0(0.6 to 80.6)
OG00233.3(0.8 to 90.6)
OG003
Day 12: TDV-1
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 12: TDV-2
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0022
ParticipantsOG0031
Title
Measurements
OG00050.0(28.2 to 71.8)
OG00125.0(0.6 to 80.6)
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 12: TDV-3
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 12: TDV-4
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0004.5(0.1 to 22.8)
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 15: TDV-1
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 15: TDV-2
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00036.4(17.2 to 59.3)
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 15: TDV-3
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 15: TDV-4
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 30 (Month 1): TDV-1
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 30 (Month 1): TDV-2
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 30 (Month 1): TDV-3
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 30 (Month 1): TDV-4
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 90 (Month 3): TDV-1
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 90 (Month 3): TDV-2
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 90 (Month 3): TDV-3
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 90 (Month 3): TDV-4
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 96: TDV-1
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 96: TDV-2
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 96: TDV-3
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 96: TDV-4
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 99: TDV-1
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 99: TDV-2
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 99: TDV-3
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 99: TDV-4
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 102: TDV-1
ParticipantsOG00021
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 102: TDV-2
ParticipantsOG00021
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 102: TDV-3
ParticipantsOG00021
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 102: TDV-4
ParticipantsOG00021
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 105: TDV-1
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 105: TDV-2
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 105: TDV-3
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 105: TDV-4
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 120 (Month 4): TDV-1
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 120 (Month 4): TDV-2
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 120 (Month 4): TDV-3
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
Day 120 (Month 4): TDV-4
ParticipantsOG00022
ParticipantsOG0013
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0000.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0010.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG0020.0(NA to NA)The 95% CI was not estimable as no participants had vaccine viremia.
OG003
0
0
Title
Measurements
OG0004.0(1 to 8)
OG0011.0(1 to 2)
OG0022.5(1 to 4)
TDV-4
ParticipantsOG0001
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0030
Title
Measurements
OG0003.0(3 to 3)
OG0011.0(1 to 1)
OG0021.0(1 to 1)
0
0
Day 6: TDV-2
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0021
ParticipantsOG0030
Title
Measurements
OG0023.17± NASD was not estimable for a single participant.
Day 6: TDV-3
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 6: TDV-4
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 9: TDV-1
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 9: TDV-2
ParticipantsOG0004
ParticipantsOG0013
ParticipantsOG0022
ParticipantsOG0030
Title
Measurements
OG0003.46± 0.485
OG0013.94± 0.568
OG0024.06± 1.003
Day 9: TDV-3
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 9: TDV-4
ParticipantsOG0001
ParticipantsOG0011
ParticipantsOG0021
ParticipantsOG0030
Title
Measurements
OG0003.98± NASD was not estimable for a single participant.
OG0013.90± NASD was not estimable for a single participant.
OG0023.71± NASD was not estimable for a single participant.
Day 12: TDV-1
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 12: TDV-2
ParticipantsOG00011
ParticipantsOG0011
ParticipantsOG0020
ParticipantsOG0030
Title
Measurements
OG0003.43± 0.140
OG0013.65± NASD was not estimable for a single participant.
Day 12: TDV-3
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 12: TDV-4
ParticipantsOG0001
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Title
Measurements
OG0003.80± NASD was not estimable for a single participant.
Day 15: TDV-1
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 15: TDV-2
ParticipantsOG0008
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Title
Measurements
OG0003.32± 0.172
Day 15: TDV-3
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
Day 15: TDV-4
ParticipantsOG0000
ParticipantsOG0010
ParticipantsOG0020
ParticipantsOG0030
1
1
Title
Measurements
OG00054.5
OG00125.0
OG00266.7
OG0030
After First Vaccination: Pain
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00040.9
OG00125.0
OG00266.7
OG003
After First Vaccination: Erythema
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00040.9
OG0010
OG00233.3
OG003
After Second Vaccination: Any Solicited Local AEs
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00068.2
OG00150.0
OG00266.7
OG003
After Second Vaccination: Pain
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00059.1
OG00150.0
OG00266.7
OG003
After Second Vaccination: Erythema
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00031.8
OG0010
OG00233.3
OG003
After Second Vaccination: Swelling
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0009.1
OG0010
OG0020
OG003
1
1
Title
Measurements
OG00068.2
OG00175.0
OG002100.0
OG0030
After First Vaccination: Headache
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00050.0
OG00150.0
OG00233.3
OG003
After First Vaccination: Myalgia
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00040.9
OG00125.0
OG002100.0
OG003
After First Vaccination: Asthenia
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00031.8
OG00125.0
OG00266.7
OG003
After First Vaccination: Malaise
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00054.5
OG00125.0
OG002100.0
OG003
After First Vaccination: Fever
ParticipantsOG00022
ParticipantsOG0014
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0004.5
OG0010
OG0020
OG003
After Second Vaccination: Any Solicited Systemic AE
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00027.3
OG0010
OG00266.7
OG003
After Second Vaccination: Headache
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00013.6
OG0010
OG00266.7
OG003
After Second Vaccination: Myalgia
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG0009.1
OG0010
OG0020
OG003
After Second Vaccination: Asthenia
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00018.2
OG0010
OG0020
OG003
After Second Vaccination: Malaise
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00013.6
OG0010
OG00266.7
OG003
1
1
Title
Measurements
OG00063.6
OG00175.0
OG00266.7
OG0030
After Second Vaccination
ParticipantsOG00022
ParticipantsOG0012
ParticipantsOG0023
ParticipantsOG0031
Title
Measurements
OG00036.4
OG0010
OG002100.0
OG003
1
0
1
0
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.
0.0
(NA to NA)
The 95% CI was not estimable as no participants had vaccine viremia.